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Endofin is an endosomal protein that localizes to the early endosomes. It is 
characterized by a zinc-finger domain, referred to as the FYVE domain. This domain 
targets Endofin to the early endosomes by binding to the phosphatidylinositol 3-
phosphate within the endosomal membrane. Endofin functions as a regulator of 
specific signaling pathways, such as BMP and TGF-β signaling, whereby it plays the 
role of an adaptor. Furthermore, it has been identified as a novel tyrosine 
phosphorylation target downstream of EGFR.  
To date, there have only been a few functional studies published on Endofin 
and consequently our understanding of Endofin’s functions is very limited, especially 
with respect to EGFR signaling. In this study, an attempt was made to map the 
signaling events associated with Endofin following activation of EGFR with EGF. 
Tyrosine phosphorylation of Endofin was shown to be dependent on clathrin-
dependent endocytosis of EGFR and EGFR activity. Phosphatidylinositol 3-kinase 
activity and FYVE domain-mediated localization of Endofin to early endosomes were 
found to be necessary for the tyrosine phosphorylation of Endofin. Tyrosine 515 was 
identified as a major phosphorylation site on Endofin however disruption of 
phosphorylation at Y515 neither affects Endofin’s localization nor its co-localization 
with EGFR at the endosomes. Instead, the abrogation of Y515 phosphorylation and 
the mislocalization of Endofin were found to enhance the amplitude of the MAPK 
cascade and increase cell proliferation, suggesting a possible role of Endofin in the 
modulation of MAPK pathway. Collectively, this study has identified a novel 








1.1 Cellular communication  
Cellular communication is a core aspect of a functional biological system. 
From multicellular to unicellular organisms, communication between organs, tissues 
and even single cells plays a decisive role in development and survival. This 
communication not only determines vital cellular processes such as proliferation, 
differentiation and apoptosis, it also allows cells to react appropriately to the ever-
changing surrounding environment (Pawson, 1995).  
Cellular communication comprises of a complex system of signaling 
networks, with each signaling pathway described as a “signal transduction” (King, 
2010). A signal transduction begins with the extracellular signals, usually in the form 
of endocrine, paracrine hormones, or signaling molecules, binding to specific proteins 
on the cell membrane. The binding of these specific membrane proteins activates 
signaling cascades that transverse across the cytosol and into the nucleus, ultimately 
leading to changes in gene expression which will determine the correct biological 
response. In addition, these signaling networks are controlled by finely-tuned positive 
and negative feedback cascades and the balance between them determines the final 
outcome (Freeman, 2000). Conversely when the balance between the two networks is 
disrupted, it often results in uncontrollable proliferation or untimely cell death which 
manifests in the form of diseases, such as cancer (Hanahan, 2000). Hence, it is crucial 
for the cells to interpret these cellular signals with the utmost accuracy in order for 
them to give the correct response. This ability of the cells to perceive and respond 
correctly to the microenvironment therefore forms the basis of development, tissue 




signaling in cell biology, tremendous effort has been invested in trying to comprehend 
the signaling networks involved, in both the normal and diseased state. 
 
1.2 Receptor tyrosine kinase  
Receptor tyrosine kinases (RTKs) are a class of transmembrane proteins that 
play a pivotal role in cellular communication. They act as primary mediators in the 
interpretation of extracellular mitogen activity and have a high-affinity for many 
growth factors which allows them to regulate and coordinate cellular processes (Fantl 
et al, 1993; Schlessinger and Ullrich, 1992). Binding of these external signals/ligands 
to the RTKs at the plasma membrane activates the tyrosine kinases of the receptors 
which in turn initiates signaling cascades within the cells. The signal is eventually 
conveyed into the nucleus, leading to the transcription of specific genes. In this way, 
RTKs integrate these external signals with the various internal signal transduction 
pathways and activate gene transcription within the cells, allowing the cell to respond 
to the extracellular stimuli (Kholodenko, 2006).  
Currently, there are 58 receptor tyrosine kinase proteins identified out of the 
90 unique tyrosine kinase genes present in the human genome (Robinson et al., 2000) 
and they can be classified into 20 subfamilies based on their structural characteristics 
(Grassot et al., 2003; Lemmon and Schlessinger, 2010). All RTKs have a general 
structure consisting of an extracellular N-terminal region, a hydrophobic 
transmembrane domain (25-38 amino acids) and an intracellular C-terminal region 
(Grassot et al., 2006). The extracellular N-terminal region of the RTKs is made up of 
various conserved elements such as the immunoglobulin (Ig)-like or epidermal growth 
factor (EGF)-like domains, fibronectin type III repeats or cysteine-rich regions which 




ligand-binding site which binds to the receptor’s specific ligand is also situated at the 
extracellular N-terminal region. The C-terminal region displays the highest level of 
conservation with the tyrosine kinase catalytic domain, which is responsible for 
receptor autophosphorylation and the phosphorylation of RTK substrates (Yarden and 
Ullrich, 1988).         
 
1.3       Epidermal growth factor receptor  
Epidermal growth factor receptor (EGFR), a typical RTK, lies at the head of a 
complex signal transduction network that modulates numerous cellular processes. 
EGFR was first discovered by Stanley Cohen in 1980 as a cell surface receptor for the 
epidermal growth factor (EGF) he extracted from salivary gland extracts in 1962 
(Cohen, 1962; Cohen et al., 1980). Since then, there have been extensive studies done 
on EGFR, including the characterization of the protein and its functional roles in the 
regulation of important cellular processes such as cell growth and differentiation 
(Yarden and Sliwkowski, 2001). EGFR (also known as ErbB1) belongs to the ErbB 
family of receptors and is classified under subclass I of the superfamily of RTKs. 
Besides EGFR, there are 3 other ErbB family members, namely ErbB2, ErbB3 and 
ErbB4, each playing different roles in development and differentiation (Britsch, 
2007).  
The importance of EGFR in regulating mammalian development has been 
asserted through the use of genetically modified transgenic mice in which the 
expression of both the receptor and its ligands has been manipulated. Depending on 
the genetic background of the mice, EGFR knockout can be either embryonic or 
perinatal lethal and generally carry abnormalities in multiple organs, including lung, 




(Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995). EGFR 
deficient mice have been shown to develop progressive neurodegeneration in the 
frontal cortex, olfactory bulb and thalamus postnatal in a strain dependent manner 
(Kornblum et al., 1998; Sibilia et al., 1998). In addition, mice with an EGFR kinase 
domain mutation or expressing a dominant-negative EGFR exhibit impaired ductal 
growth, indicating that EGFR is essential for promoting ductal growth in the 
mammary glands (Fowler et al., 1995; Xie et al., 1997). Contrary to the lethal effects 
of EGFR knockouts, mice that lack EGFR ligands display less severe phenotypes, 
demonstrating the redundancy built into EGFR signaling. For instance, TGF-α null 
mice are viable, fertile and display eye and hair follicles abnormalities (Luetteke et 
al., 1993; Mann et al., 1993). Female mice with triple deficiency of EGF, 
amphiregulin and TGF-α show reduced mammary gland ductal outgrowth during 
puberty and display difficulties in nursing their young, indicative of possible 
collaborative roles of the three ligands in mammopoiesis and lactogenesis (Luetteke et 
al., 1999). In gastrointestinal development, mice lacking all three EGFR ligands 
(EGF, amphiregulin and TGF-α) present with spontaneous duodenal lesions and 
decreased cell proliferation in crypts leading to truncated ileal villi (Troyer et al., 
2001).   
The wide variation of phenotypes arising from EGFR null mice demonstrate 
the extensive role that EGFR plays in tissue development and maintenance. While 
EGFR is one of the main regulators of cellular processes such as cell proliferation, 
differentiation, and migration, aberrant signaling activity of this receptor has been 
shown to play a key role in the development and growth of tumor cells. Numerous 
studies on the involvement of EGFR in various human cancers, including breast, 




others have been reported (Salomon et al., 1995). Dysregulation of EGFR as detected 
in human cancers usually occur by several mechanisms, such as EGFR 
overexpression, activating mutations, defective or limited receptor downregulation, 
activation of the autocrine growth factor loop and deficiency of specific phosphatases 
that deactivate EGFR (Bhargava et al., 2005; Lee et al., 2005; Zandi et al., 2007). In 
addition, mutations of the EGFR gene that lead to the production of different receptor 
forms have also been reported in certain cancers. One of the most common forms of 
mutation is the mutation that results in the expression of a truncated EGFR in 
glioblastoma, termed EGFRvIII (Collins, 1994). This truncated EGFR lacks 
information from exons 2-7, thereby resulting in the constitutive ligand-independent 
activation of the receptor tyrosine kinase (Chu et al., 1997).     
The EGFR protein is made up of 1186 amino acids after cleavage at the N-
terminal of its 1210 amino acids polypeptide precursor. 20% of the receptor is N-
linked glycosylated and this is required for the translocation of the receptor to the cell 
membrane and its ligand binding ability (Slieker et al., 1986). The structural features 
of EGFR consist of a glycosylated, extracellular N-terminal region (621 amino acids), 
a transmembrane segment (amino acids 622-644), followed by an intracellular  
domain that contains a juxtamembrane region, a tyrosine kinase and a C-terminal 
region which consists of several phosphorylation sites (Normanno et al., 2005)(Fig. 
1.3). The extracellular N-terminal sequence of EGFR, also known as ectodomain, 
contains 4 domains, L1, CR1, L2 and CR2. The ligand-binding pocket is located 
between L1 and L2 domains and a dimerization arm is present between them. The 
juxtamembrane region of EGFR has been shown to possess a few regulatory 
functions. For instance, the dileucine motif, L679/680, in the juxtamembrane region 




the internal vesicles of multivesicular bodies (Kil and Carlin, 2000). Several proteins 
were also found to bind to the juxtamembrane region of EGFR, namely eps8 and 
calmodulin and these interactions prevented the phosphorylation of Thre654 by 
protein kinase C (Castagnino et al., 1995; Li and Villalobo, 2002; Martin-Nieto and 
Villalobo, 1998). The C-terminal region of EGFR contains several tyrosine residues, 
which has been shown to modulate EGFR signaling upon phosphorylation and 
serine/threonine residues whose phosphorylation are important for receptor down-
regulation and sequences required for endocytosis.   
 
L1 CR1 L2 CR2 JM kinase CT 
151        312         481        621  644        687                          955                  1186        
Ligand binding domain  
Fig. 1.3 Schematic representation of EGFR structural domains  
The ligand binding pocket is located between L1 and L2 domain while the 
transmembrane region is between CR2 and juxtamembrane region. The abbreviations 
used: L and CR are for ligand binding and cysteine-rich domains, JM and CT refer to 
juxtamembrane region and carboxyl-terminal respectively.  
 
 
1.3.1    EGFR activation 
To activate and initiate the downstream signaling cascades, EGFR has to first 
bind to its ligand. Ligands that bind to EGFR are known as EGF-related peptide 
growth factors (Yarden, 2001; Yarden and Sliwkowski, 2001). Their binding 
specificities are conferred by an EGF-like domain (~ 60 amino acids) which is made 
up of three disulfide-bonded intramolecular loops. In addition to the EGF-like 
domain, they also possess other structural motifs, such as heparin-binding sites, 




synthesized as active transmembrane precursors, which can interact with the receptors 
on neighboring cells, and are released by proteolysis as soluble growth factors. The 
growth factors that bind specifically to EGFR include EGF, amphiregulin (AR) and 
transforming growth factor-α (TGF-α). Betacellulin (BTC), heparin-binding EGF 
(HB-EGF) and epiregulin (EPR) are able to bind to both EGFR and ErbB4, due to 
their dual-specificity property (Jones et al., 1999).  
Ligand binding results in the exposure of a dimerization arm that induces the 
receptors to either homo- or heterodimerize with itself or other ErbB receptors. The 
formation of various EGFR dimers is dependent on the binding ligand and the ErbB 
receptors present on the cell surface. EGFR homodimers are better characterized 
comparing to its heterodimers. The most common EGFR heterodimer formed is the 
EGFR-ErbB2 heterodimer as ErbB2 is the preferred dimerization partner of all ErbB 
receptors (Graus-Porta et al., 1997). Receptor dimerization not only amplifies signal 
strength but it also leads to signal diversification as different receptor dimers can 
result in different signaling outputs. For instance, EGF-activated EGFR-ErbB2 
heterodimer was shown to be endocytosis-deficient in comparison to EGFR 
homodimers (Haslekas et al., 2005; Wang et al., 1999). In addition, EGF activated 
EGFR, but not EGFR-ErbB4 heterodimer, was able to recruit Grb2 (Olayioye et al., 
1998). Hence, the diversification of signals arises from the unique properties acquired 
by the heterodimer as a whole and is not due to the signaling properties of the 
individual receptors in the dimer. 
EGFR dimerization induces the activation of its tyrosine kinase and 
autophosphorylation of the receptors whereby several tyrosine residues in the C-
terminal region are phosphorylated. These phosphorylated residues in turn recruit a 




PTB (phosphotyrosine binding) or SH2 (Src-homology 2) domains. The substrates 
that bind to the phosphorylated tyrosine residues include adaptors like, Grb2, Shc and 
Dok-R that bind to pY1068, pY1086 and pY1148, pY1173 and pY1086, pY1148 
respectively, phospholipase PLC-γ which binds to pY1173 and pY992, phosphatase 
like PTB-1B and SHP-1 are recruited by pY992, pY1148 and pY1173 respectively, 
ubiquitin ligase c-Cbl that interacts with pY1045, transcription factor Stat5 binds to 
pY978, pY998 and tyrosine kinase Abl binds to pY1086 (Jorissen et al., 2003; 
Schulze et al., 2005)(Fig. 1.3.1). The presence of multiple binding sites of a substrate 
on EGFR indicates that the differential substrate binding pattern, which depends on 
the ligand, dimerization partner, substrate availability and competing substrates, can 
occur and this contributes to the diverse signal outputs. Besides autophosphorylation 
of residues, the C-terminal region of EGFR can also be phosphorylated by other 
intracellular tyrosine kinases, such as the Src kinase and Jak2 kinase (Lombardo et al., 
1995; Yamauchi et al., 1997). Jak2 was proposed to phosphorylate Tyr1068 on EGFR 
upon growth hormone stimulation, suggesting a potential cross-talk signaling pathway 
between the cytokine and growth factor receptor. Reports have suggested that Tyr845, 
Tyr891, Tyr920, Tyr1101 were phosphorylated by Src and src-mediated 
phosphorylation of EGFR was shown to be involved in the regulation of the growth 
factor receptor function and signal transduction (Biscardi et al., 1999; Stover et al., 
1995). The interaction of EGFR with its substrates greatly enhances its substrate 
phosphorylation efficiency and assists in the formation of highly organized 
multicomponent signaling complexes, therefore propagating the signal further 







Fig. 1.3.1 Schematic representation of phosphorylated tyrosine residues on       
EGFR and its binding substrates 
 
Several substrates have more than one phosphotyrosine binding sites on the 
intracellular portion of EGFR. This suggests that differential binding patterns of the 













1.3.2 EGFR signaling pathways 
Based on the diversity of protein complexes formed at EGFR, multiple 
signaling pathways can be elicited from the activated EGFR. The major signaling 
pathways activated by EGFR are the Ras/Raf/MEK/ERK, PI3K/PDK1/Akt, PLC-
γ/DAG/IP3 and JAK/STAT pathways. All of these signaling pathways contribute to 
the regulation of cellular processes such as cell proliferation, survival, adhesion and 
migration (Yarden and Sliwkowski, 2001). 
 
1.3.2.1 Ras/Raf/MEK/ERK pathway 
The Ras/Raf/MEK/ERK pathway is one of the best characterized signaling 
pathways emanating from EGFR (Fig. 1.3.2.1). This pathway begins with the adaptor 
protein, Grb2, which binds constitutively to the proline-rich sequences of a guanine 
nucleotide exchange factor (GEF), Son of Sevenless (SOS), in the cytosol under 
normal circumstances, via its SH3 domain. However upon EGFR activation, Grb2 is 
recruited to the C-terminus of EGFR where it can either bind directly to pY1068 and 
pY1086 or indirectly, through EGFR bound tyrosine phosphorylated Shc, via its SH2 
domain (Sasaoka et al., 1994). The recruitment of Grb2/SOS complex to the receptor 
at the plasma membrane allows SOS to interact with the membrane-associated Ras, a 
small guanosine triphosphatase (GTPase), thereby resulting in the exchange of the 
Ras-bound GDP for GTP and the activation of Ras. The activated Ras in turn recruits 
and activates one of its effector proteins, Raf, a serine/threonine kinase by displacing 
it from an adaptor protein, namely 14-3-3 (Hallberg et al., 1994). The activation of the 
Raf kinase triggers the activation/phosphorylation of a series of serine/threonine 
kinases consecutively, namely the mitogen activated extracellular signal regulated 




activated ERK phosphorylates a wide range of substrates either in the cytosol or in the 
nucleus. ERK nuclear substrates include transcription factors like Elk1, c-fos, c-myc, 
c-jun, which are key regulators of proliferation, apoptosis, and differentiation 
(Krishna and Narang, 2008; Yoon and Seger, 2006). On top of this, the activation of 
ERK also acts as a negative feedback loop for this pathway. Reports have shown that 
the phosphorylation of SOS by ERK caused the dissociation of SOS from Grb2 and 
ERK phosphorylation of Raf inhibited Raf/Ras interaction, both resulting in the 
attenuation of the Ras/Raf/MEK/ERK signaling pathway (Dougherty et al., 2005; 
















Fig. 1.3.2.1 Ras/Raf/MEK/ERK pathway 
This pathway begins with Grb2, in association with SOS, that binds to activated 
EGFR either directly or via Shc. SOS then activates Ras, promoting the exchange of 
its GDP for GTP and  this in turn leads to the consecutive activation of a series of 
kinases, namely, Raf, MEK and ERK. The activated ERK translocates into the 
nucleus and activates the transcription of genes through the phosphorylation of 











1.3.2.2 PI3K/PDK1/Akt pathway 
In order for the cells to proliferate continuously, programmed cell death has to 
be inactivated. PI3K/PDK1/Akt pathway plays a major role in the anti-apoptotic 
effects of EGFR activation (Fig. 1.3.2.2). Phosphoinositide-3-kinases (PI3K) catalyze 
the phosphorylation on the 3′ position of phosphatidylinositols (PtdIns). They are 
categorized into three classes according to their subunit structures and lipid substrates. 
The PI3K that is activated by EGFR belongs to class 1a. PI3K is activated upon the 
binding of its p85 subunit either directly to EGFR on pY920 or indirectly via Grb2 
(Stover et al., 1995). PI3K then phosphorylates phosphatidylinositol-4,5-bisphosphate 
(PIP2) at the plasma membrane to generate phosphatidylinositol-3,4,5-trisphosphate 
(PIP3). Serine/threonine kinase Akt then binds to PIP3 at the plasma membrane via its 
PH (Pleckstrin homology) domain and is subsequently activated through 
phosphorylation by phosphoinositide-dependent kinase-1 (PDK-1) and other kinases. 
Phosphorylated Akt promotes cell survival through several mechanisms such as the 
downregulation of pro-apoptotic genes expression, activation of pro-survival genes 
transcription and the blocking of key pro-apoptotic proteins activities. For example, it 
has been reported that transcription factor FKHRL1 was exported out of the nucleus 
upon phosphorylation by Akt and became sequestered by 14-3-3 proteins in the 
cytoplasm. This prevents further transcription of death genes such as Fas-L and Bim 
(Brunet et al., 1999). At the same time, phosphorylation and activation of IκB kinase 
α (IKK) by Akt leads to the phosphorylation of IκB which targets it for degradation 
(Kane et al., 1999; Ozes et al., 1999). This in turn allows the nuclear translocation and 
activation of NFκB and the subsequent transcription of NFκB-dependent pro-survival 
genes such as Bcl-XL (Barkett and Gilmore, 1999). In the inhibition of pro-apoptotic 




its sequestration by 14-3-3 proteins and thus prevents it from counteracting the actions 
of other pro-survival proteins, like Bcl-2 or Bcl-XL (Datta et al., 1997). Procaspase 9, 
is another substrate of Akt, in which phosphorylation blocks its intrinsic protease 






Fig. 1.3.2.2 PI3K/PDK1/Akt pathway 
PI3K is activated upon binding to EGFR via its p85 subunit and the activated PI3K 
generates PIP3 by phosphorylating PIP2. PIP3 activates Akt by recruiting both Akt and 
PDK1 to the same location at the plasma membrane, therefore allowing PDK1 to 
phosphorylate Akt at close proximity. Activated Akt then promotes cell survival 
through a number of mechanisms, such as by preventing the translocation of 
transcription factor such as, FKHRL1 into the nucleus for the transcription of death 
genes, promoting translocation of NFκB to activate the transcription of pro-survival 






1.3.2.3 PLC-γ/DAG/IP3 pathway 
Besides affecting the proliferation of the cells, EGF stimulation also exerts an effect 
on the cells’ phospholipids metabolism, such as the production of phosphatidic acid 
(PA) and arachidonic acid (AA). Phospholipase C-γ (PLC-γ) is one of the enzymes 
involved in phospholipids metabolism that is directly activated by EGFR. PLC-γ is 
activated upon binding directly to pY1173 and pY992 of EGFR via its SH2 domains 
and is in turn phosphorylated by EGFR on Y783 and Y1254 (Carpenter and Ji, 1999). 
These phoshorylated residues are shown to enhance the efficiency of the enzyme; 
however they may not be necessary for its activation (Hernandez-Sotomayor and 
Carpenter, 1993; Nishibe et al., 1990). The activated PLC-γ plays a significant role in 
membrane signaling, where it generates major second messengers 1,2-diacylglycerol 
(DAG) and inositol 1,3,5-trisphosphate (IP3) by catalyzing the hydrolysis of  PIP2 
(Fig. 1.3.2.3). IP3 being soluble, diffuses through the cytosol, binds to the IP3 receptors 
located on the endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR) 
membrane, causes the opening of calcium channels and the subsequent release of 
calcium (Ca2+). This release of Ca2+ allows EGFR to activate Ca2+-dependent 
pathways such as Ra (one) and NFκB pathways (Hofer et al., 1998; Sun and 
Carpenter, 1998). The other second messenger, DAG, remains at the membrane where 
it can act as a coactivator of the serine/threonine kinase, protein kinase C (PKC), 
which in turn leads to the engagement of other signaling pathways such as JNK and 
MAPK pathways (Marais et al., 1998; McClellan et al., 1999). In addition to its 
function as a PKC activator, DAG is also suggested to be a negative modulator of Rac 






Fig. 1.3.2.3 PLC-γ/DAG/IP3 pathway 
EGFR-activated PLC-γ catalyses the hydrolysis of PIP2 to generate second 
messengers IP3 and DAG. IP3 binds to the IP3 receptors located on the ER membrane 
to trigger the release of Ca2+ and subsequent activation of Ca2+–dependent pathways 
such as Ra (one) and NFκB. On the other hand, the membrane bound DAG activates 










1.3.2.4 JAK/STAT pathway 
The JAK/STAT pathway was initially shown to be elicited by cytokine 
receptors, however signal transducers and activators of transcription (STAT) proteins, 
in particular STAT1, STAT3 and STAT5, have been implicated in EGFR signaling as 
well. In general, growth factor or cytokine signaling results in the binding of STAT 
proteins to the growth factor receptor or cytokine receptor/Janus kinase (JAK) 
complex via its SH2 domains and subsequent phosphorylation of crucial tyrosine 
residues on STAT proteins by the kinases. The activated STAT proteins then homo- 
or heterodimerize and translocate into the nucleus where they activate the 
transcription of target genes. STAT1, STAT3 and STAT5 are phosphorylated on 
Tyr701, Tyr705 and Tyr694 respectively and this phosphorylation mediates their 
activation and dimerization (Rane and Reddy, 2002). On top of this, regulation of the 
STAT pathway by EGFR can occur in a JAK-dependent or a JAK-independent 
manner. For instance, it was reported that EGFR phosphorylation of STAT1 induced 
the multicomponent complex formation between STAT1, STAT3, JAK1 and JAK2, 
and their involvement in EGFR-mediated cell migration (Andl et al., 2004). Evidence 
on Jak-independent activation of the STAT pathway by EGFR has been presented as 
well (Leaman et al., 1996). Of particular interest is the activation of STAT5b, where 
Tyr845 of EGFR and src kinase have been shown to be necessary for EGF-induced 
tyrosine phosphorylation and transcriptional activation of STAT5b (Kloth et al., 








1.3.2.5 Src kinases 
Src kinase’s involvement in EGFR signaling has been well documented and 
data from these studies indicate that Src plays a major role in the signaling pathway 
(Erpel and Courtneidge, 1995). However, it is unclear whether Src is acting as an 
effector or a coactivator of EGFR. In certain circumstances, such as in cells that 
overexpress EGFR, Src kinase activity has been demonstrated to be greatly dependent 
on EGFR activation (Mao et al., 1997). Additionally, Src kinase has been reported to 
associate with EGFR at pY891, pY920 and pY1110 via its SH2 domain, and these are 
essentially sites proposed to be phosphorylated by Src kinase itself (Lombardo et al., 
1995). On the other hand, certain functions of EGFR are regulated by Src-dependent 
phosphorylation of EGFR. For example, Tyr845 of EGFR was reported to be 
phosphorylated by Src (Biscardi et al., 1999; Sato et al., 1995). pY845 was shown to 
be required for EGF-induced DNA synthesis (possibly through STAT5b) and EGFR’s 
interaction with mitochondrial cytochrome-c oxidase subunit II (CoxII) which was 
necessary for the regulation of cell survival (Boerner et al., 2004; Kloth et al., 2003; 
Tice et al., 1999). Tyr920 is another Src kinase phosphorylation site on EGFR, which 
upon phosphorylation, forms the binding site for p85 subunit of PI3K and facilitates 
the subsequent activation of PI3K by EGFR. In addition to its ability to phosphorylate 
EGFR directly, Src is also involved in the transactivation of EGFR by stimuli other 
than EGF, such as G-protein coupled receptors (GPCR) and integrins (Prenzel et al., 
2000).     
Not only does Src kinase regulate EGFR signaling by acting on the receptor or 
its downstream substrates directly, it can also act through modulation of EGFR 
endocytosis and degradation. A study demonstrated that overexpression of Src 




EGFR endocytosis rate, EGF-induced phosphorylation of clathrin and redistribution 
to the cell periphery were also delayed and inhibited in cells that were either treated 
with Src kinase inhibitor or lack of Src expression (Wilde et al., 1999). Another 
mediator of EGFR endocytosis whose activity is regulated by Src kinase is dynamin, a 
GTPase responsible for catalyzing the scission of endocytic vesicles from the plasma 
membrane (Mettlen et al., 2009). Dynamin is phosphorylated by Src kinase at Tyr597 
and this phosphorylation was shown to be necessary for dynamin’s self-assembly and 
GTPase activity. Expression of an Y597F dynamin mutant inhibited EGFR 
internalization, therefore indicating the dependency of EGFR endocytosis on Src 
kinase activity (Ahn et al., 2002). In EGFR degradation, Cbl, an E3 ubiquitin ligase, 
modulates the process through ubiquitination of EGFR. Cbl is, in turn, negatively 
regulated by Src kinase, through phosphorylation that alters its conformation and 
destabilizes its interaction with the E2 ubiquitin conjugating enzyme, UbcH7 
(Yokouchi et al., 2001). Consequently, in Src-transformed cells, EGFR ubiquitination 
and endocytosis were impaired, as Src promoted the phosphorylation and degradation 
of Cbl (Bao et al., 2003). This ultimately led to the upregulation of EGFR level and 
signaling in the cell. Collectively, these studies are an indication of Src-mediated 
regulation of EGFR endocytosis/degradation and signaling.                   
 
1.4       EGFR endocytosis 
Endocytosis is a complex process that involves the internalization of 
extracellular molecules, ligands, lipids and plasma membrane proteins. It is a 
mechanism utilized by the cells to maintain homeostasis and communication with 
their extracellular environment. Endocytosis of EGFR is one of the most extensively 




characterized based on the activation of EGFR upon EGF binding. It is also the 
prototypic model for the study of endocytosis of other RTKs (Sorkin and Goh, 2008).  
 
1.4.1    Trafficking of EGFR in the absence of ligands 
The basal turnover rate of unstimulated EGFR differs between cell lines and it 
seems to be dependent on the EGFR expression level of the cells. The general trend 
observed is that the EGFR turnover rate has a reciprocal correlation relationship with 
their expression level, which is probably due to the saturability of their internalization 
and degradation steps of trafficking. For instance, the receptor turnover rate in cells 
expressing low to moderate level of EGFR (<200,000/cell) is in the range of 6-10h, 
whereas in cells overexpressing EGFR, such as human epithelial carcinoma A431, 
their turnover rate could be 24h or longer (Stoscheck and Carpenter, 1984a; Stoscheck 
and Carpenter, 1984b). This goes to show that endocytosis of EGFR is occurring 
constantly, even in the absence of ligands or receptor activation. However, to 
maintain a relative amount of receptors at the cell surface during steady-state 
condition, the recycling of EGFR back to the plasma membrane has to occur at a 
much higher rate than its internalization. In most cells, this is the case where EGFR is 
constitutively internalized with a rate constant of ~0.02-0.05 min-1 and recycled back 
to the cell surface with a rate constant of ≥0.2 min-1 (Wiley, 2003). This ultimately 
results in the majority of EGFR localized at the plasma membrane and a small 
endosomal pool of endocytosed EGFR at steady-state.  
   
1.4.2    Ligand-induced endocytosis 
Apart from the activation of EGFR and its various signaling pathways, EGF 




EGFRs then enter the endocytic pathway and are sorted into various endosomal 
compartments which target them to either degradation or recycling back to the plasma 
membrane. EGFR endocytosis occurs by various mechanisms, which can be classified 
into two main groups, namely clathrin-dependent and clathrin-independent (Sorkin 
and Goh, 2008). These different endocytic mechanisms have an effect on the fate of 
the receptors. There is evidence demonstrating that receptors endocytosed through 
clathrin-dependent pathway are preferentially recycled back to the plasma membrane 
whereas those endocytosed through clathrin-independent pathway are targeted for 
degradation (Sigismund et al., 2008). 
   
1.4.2.1 Clathrin-independent endocytosis (CIE) 
   Clathrin-independent endocytosis (CIE) can occur in many forms and is less 
well studied compared to clathrin-dependent endocytosis (CDE). Cell surface 
transmembrane proteins that undergo CIE usually lack the cytoplasmic sequences 
required for recruitment into the clathrin-coated pits. However, EGFR, which can be 
internalized by CDE, has been observed to undergo CIE as well. There are several 
mechanisms of CIE that can be utilized by the cell, such as actin-driven 
macropinocytosis and phagocytosis, dynamin-dependent caveolin-1 associated 
caveolar endocytosis, a CIE pathway that involves CDC42, ADP-ribosylation factor 1 
(ARF1), actin and another mode of CIE which is dynamin-independent and is 
associated with ARF6 GTPase (Kumari and Mayor, 2008; Mayor and Pagano, 2007).   
   CIE of EGFR was first observed in studies performed in A431 cells. Plasma 
membrane ruffling and formation of labeled EGF-containing micro- and 
macropinocytic vesicles with no clathrin coat were induced upon EGF stimulation of 




observations were also made by confocal microscopy in EGF-treated COS cells 
(Yamazaki et al., 2002). Recently, a novel endocytotic mechanism of EGFR was 
observed in a number of different cell lines. The study showed that EGFR was 
internalized by EGF-induced dorsal waves that subsequently led to the formation of 
tubular-vesicular structures containing EGF/EGFR complexes and this process 
required dynamin, PI3K and EGFR activities (Orth et al., 2006). Besides actin-based 
CIE mechanisms, EGFR was also demonstrated to be internalized by caveolar 
endocytosis in Hela, CHO and NR6 cells (Sigismund et al., 2005).      
   In summary, EGFRs are able to enter into the cells through various CIE 
mechanisms, via pinocytic vesicles, ruffle-generated endocytic structures, or even 
cholesterol-rich lipid rafts and caveolae. Overall, the internalization rate of EGFR by 
CIE pathways is significantly slower than those of CDE but faster than the 
constitutive internalization of EGFR.  
   
1.4.2.2 Clathrin-dependent endocytosis (CDE) 
CDE is one of the better studied internalization route taken by EGFR. 
Although this pathway has been extensively characterized, its control is complex as 
many proteins are implicated in the process. Endocytosis begins with the relocation of 
EGFR into clathrin-coated pits (CCP) on the plasma membrane upon receptor 
activation. Clathrin-coated pits are small areas of the plasma membrane where the 
cytoplasmic surface is covered by clathrin triskelions. Clathrin triskelions are 
essentially a polyhedral clathrin lattice composed of three clathrin heavy chains and 
three clathrin light chains. EGFR is recruited into the CCPs by clathrin adaptor 
complex 2 (AP2), the main cargo binding protein of the coated pits, which binds to 




motif, Y974RAL motif, was found to interact directly with the μ2 subunit of AP2. 
However, mutations in the motif and the binding region of AP2 μ2 subunit for the 
motif did not lead to any decrease in EGFR internalization, indicating that this 
Y974RAL/AP2 interaction is not essential for EGFR internalization (Nesterov et al., 
1999; Sorkin et al., 1996). A dileucine motif, Leu1010/1011, is shown to mediate the 
phosphorylation of β2 subunit of AP2, thereby suggesting a possible interaction 
between the receptor and AP2 (Huang et al., 2003; Sorkin et al., 1996). However, this 
motif was also reported not necessary for EGFR internalization (Huang et al., 2003). 
Although there are confounding evidence on the effect of AP2 depletion on EGFR 
endocytosis among different studies (Huang et al., 2004; Johannessen et al., 2006), 
depletion of AP2 μ2 subunit did not cause any reduction in EGFR endocytosis rate 
(Motley et al., 2003). In summary, the precise role of EGFR and AP2 interaction in 
EGFR internalization remains unknown.  
The kinase activity of EGFR plays a regulatory role in CDE as well. This is 
supported by evidence of low EGFR internalization rate in cells expressing kinase-
dead EGFR and failure to recruit EGFR to the CCPs in the presence of tyrosine kinase 
inhibitors (Honegger et al., 1987; Sorkina et al., 2002). As activation of EGFR kinase 
results in the phosphorylation of residues in the C-terminus of EGFR by itself or other 
kinases, certain phosphorylation sites of EGFR have been implicated in the 
modulation of EGFR endocytosis. The mutation of certain tyrosine phosphorylation 
sites led to a reduction in the EGFR internalization rate (Sorkin et al., 1991b). 
Particularly, mutation of the Grb2 binding sites (Tyr1068 and Tyr1086) completely 
abolished EGFR endocytosis in porcine aortic endothelial (PAE) cells, which may be 
attributed to the inefficient recruitment of EGFR to CCPs (Jiang et al., 2003). 




expression of these phosphorylation-deficient mutants impaired receptor endocytosis. 
Interestingly, the phosphorylation of Ser1039 and Thre1041 of these mutants was 
found to be elevated and could be blocked by a p38 MAP kinase inhibitor (Tong et 
al., 2009).  
Growth factor receptor-bound protein 2 (Grb2) is an adaptor protein that is 
well-characterized for its role in Ras/Raf/MEK/ERK pathway. Due to its ability to 
bind to EGFR on its phosphotyrosines, Grb2 is implicated in the regulation of EGFR 
endocytosis as well. In addition to the evidence mentioned earlier, various other 
studies also demonstrated the importance of Grb2 in EGFR endocytosis. For instance, 
Grb2 was detected at the CCPs together with EGFR and mutations in its SH3 domains 
affected the formation of CCPs (Johannessen et al., 2006). Furthermore, the EGFR 
internalization rate was dramatically reduced in PAE and Hela cells depleted of Grb2. 
Inhibition of Grb2/EGFR interaction with a peptide corresponding to the SH2 domain 
of Grb2 also blocked EGFR endocytosis (Jiang et al., 2003; Wang and Moran, 1996).  
Being an adaptor protein, Grb2 is able to bind to many other proteins via its 
SH3 domains and thereby coupling the functions of its interacting proteins to that of 
EGFR. The E3 ubiquitin ligase, Cbl is a Grb2 interacting protein as well as a major 
player in EGFR endocytosis and degradation. Besides interaction with EGFR via 
Grb2, Cbl proteins are also able to bind directly to pY1045 of EGFR via their tyrosine 
kinase binding (TKB) domain. The importance of Cbl proteins in EGFR endocytosis 
and degradation is demonstrated in several studies. First of all, Cbl proteins were 
found to associate with EGFR at the CCPs upon EGF stimulation (de Melker et al., 
2001). Expression of c-Cbl mutants with mutations in the RING finger domain 
perturbed EGFR internalization (Jiang and Sorkin, 2003; Thien et al., 2001). In 




SH2 domain of Grb2 was able to rescue EGFR endocytosis in Grb2-depleted cells 
(Huang and Sorkin, 2005).  
Conversely, ubiquitination of EGFR by Cbl may not be required for EGFR 
internalization. This is supported by studies done with the expression of 
ubiquitination-deficient EGFR mutants. A study showed that the mutation of EGF-
induced ubiquitination sites in EGFR had no effect on its internalization rate (Huang 
et al., 2006). Furthermore, a receptor mutant that was lacking fifteen lysine residues 
and had negligible ubiquitination was still able to be internalized at the same rate as 
the wild-type EGFR, thus emphasizing the redundancy of EGFR ubiquitination for its 
endocytosis (Huang et al., 2007). Even though EGFR ubiquitination is deemed not 
essential for its endocytosis, the ubiquitination function of Cbl does play a role in 
CDE. For instance, one report showed that the ubiquitin ligase activity of c-Cbl and 
ubiquitin interacting motif (UIM) of Eps15 were required for the recruitment of 
EGFR into CCPs (de Melker et al., 2004). In another study, the overexpression of 
Cbl-binding protein Sprouty and conjugation-defective ubiquitin was able to inhibit 
EGFR recruitment to CCPs (Stang et al., 2004). Hence, the requirement for the RING 
finger domain of c-Cbl in EGFR internalization, together with these results, suggest 
that Cbl ubiquitination or RING finger domain interaction of/with other proteins does 
play a part in EGFR endocytosis. The 85kDa Cbl interacting protein (CIN85) is a Cbl-
interacting protein that forms a complex with endophillin, c-Cbl and the activated 
EGFR upon EGF stimulation. Disruption of this complex efficiently blocked EGFR 
internalization (Soubeyran et al., 2002). Abl-interactor (Abi) and intersectin (an 
endocytic scaffolding protein) are two other proteins that were shown to bind Cbl via 
their SH3 domain and regulate EGFR endocytosis through the recruitment of Cbl to 




The completion of CDE transpires when vesicle fission from the plasma 
membrane occurs, resulting in the formation of a clathrin-coated vesicle. This process 
is carried out by a GTPase called dynamin that supplies energy for the fission of the 
clathrin-coated vesicle from the membrane through GTP hydrolysis. A few proteins 
were shown to regulate CDE through their interactions with dynamin, namely the 
Cbl- and ubiquitin-interacting protein, T-cell ubiquitin ligand (TULA) and Cbl–
associated protein (CAP) (Bertelsen et al., 2007; Tosoni and Cestra, 2009). 
 
1.5   Post-endocytic trafficking of EGFR  
1.5.1   Trafficking of EGFR through the endosomes 
Upon completion of the formation of the clathrin-coated vesicle, the clathrin 
coat is shed and the resulting vesicle then fuses with the cytoplasmic vesicular 
structures to form the early endosomes. This vesicle fusion is mediated by another 
GTPase called Ras-associated protein 5 (Rab5) (Zerial and McBride, 2001). The early 
endosomes, which have a tubularvesicular structure, are highly dynamic due to the 
concomitant pinching off of vesicles and progressive fusion with each other to form 
larger sorting endosomes. Hence, within the early endosomes, EGF/EGFR complexes 
are sorted into two groups, mainly those that are destined to be degraded in the 
lysosomes and those that are to be recycled back to the plasma membrane. At this 
point, the pH within the early/sorting endosomes is mildly acidic (pH 6.0-6.5), and 
thus EGF remains associated with EGFR (Sorkin et al., 1988).   
The continuous fusion of the early endosomes with each other gradually 
changes the biochemical composition and morphology of the endosomes to that of 
multivesicular bodies (MVBs). EGFR targeted for degradation are taken into the 




compartmental interior. This creates multiple intraluminal vesicles (ILVs) within the 
organelle, which is a distinctive feature of the MVBs (Gruenberg and Stenmark, 
2004). As the ILVs membranes are not connected to the limiting membranes of the 
MVBs, receptors that are taken into the ILVs cannot be recycled (Murk et al., 2003). 
On the other hand, receptors not targeted for degradation simultaneously recycle from 
the endosomes back to the cell surface during the endosome maturation process.   
The last step of the post-endocytic trafficking of EGFR ends with the fusion of 
MVBs with lysosomes carrying hydrolytic enzymes. This results in the proteolysis of 
EGFR-containing ILVs within the MVBs, thereby marking the end of EGFR 
trafficking (Fig. 1.5).  
 
1.5.2    EGFR sorting at MVBs 
Receptor sorting at the limiting endosomal membrane is mediated by the 
endosomal sorting complex required for transport complexes (ESCRT 0-III) which 
are recruited to the endosomes through various protein and lipid interactions 
(Williams and Urbe, 2007). At this point, ubiquitination plays a major role in the 
sorting of receptors targeted for lysosomal degradation as all the ESCRT complexes 
have UIMs. It has been proposed that ubiquitinated cargo is passed from ESCRT 0 to 
III sequentially at the limiting endosomal membrane (Hurley and Emr, 2006).   
The structures of ESCRT 0 to III complexes have been characterized through 
genetic analysis of vacuole sorting in yeast (Hurley and Emr, 2006). The first 
complex in the line of receptor sorting at the limiting membrane of the MVBs is 
ESCRT 0, which consists of hepatocyte growth factor-regulated tyrosine kinase 
substrate (Hrs) and signal transduction adaptor molecule 1/2 (STAM 1/2). Hrs 




phosphatidylinositol-3-phosphate (PI3P) in the endosomal membrane while STAM 
1/2 binds to Hrs through its coiled-coiled regions (Mizuno et al., 2004; Raiborg et al., 
2001b). ESCRT 0 has been associated with the initial selection of ubiquitinated 
cargos at the limiting endosomal membrane, whereby they are shown to recruit 
clathrin and sequester ubiquitinated EGFR via their UIMs in clathrin-coated 
microdomains (Mizuno et al., 2003; Raiborg et al., 2002). The recruitment of the 
second complex, ESCRT I (hVps28, HCRP, TSG101) is facilitated by Hrs through its 
interaction with one of its component, TSG101 (Bache et al., 2004). ESCRT I, in turn 
recruits ESCRT II (EAP20, EAP30 and EAP45) from a soluble cytoplasmic pool to 
the limiting endosomal membrane, whereby it induces the oligomerization of ESCRT 
III proteins (Vps24/CHMP3).  
Functional studies of the components of the four ESCRT complexes 
demonstrated their involvement in EGFR degradation, though interaction of EGFR 
with ESCRT I, II and III has never been shown. Knock-down of Hrs or TSG101 
(ESCRT I) was shown to result in increased recycling of EGFR while absence of 
EP30 (ESCRT II) and CHMP3 (ESCRT III) only impaired degradation (Raiborg et 
al., 2008). Another study reported that depletion of EAP20 (ESCRT II) and CHMP6 
(ESCRT III) blocked lysosomal targeting and degradation of EGFR (Langelier et al., 
2006). Additionally, TSG101 and Hrs were reported to be essential for the formation 
and accumulation of ILVs in MVBs respectively (Razi and Futter, 2006). This 
indicates that the actual sorting of EGFR, which determines its fate, occurs upstream 
of ESCRT II.  
After the receptors targeted for degradation are sorted and concentrated at the 
limiting endosomal membrane, they are taken into the MVBs by inward budding. At 




the endosomal EGFR. The mechanism responsible for the formation of ILVs in 
MVBs still remains to be elucidated. However, several other proteins have been 
suggested to be involved in this process. For example, late endosomal phospholipids 
lysobisphosphatic acid (LBPA), which exists at high concentration in MVB luminal 
substructures, was speculated to take part in vesicle fission (Babst, 2005). PI3K was 
also implicated in inward vesiculation as inhibition of PI3K activity with Wortmannin 
prevented vesicle formation within MVBs and resulted in accumulation of EGFR on 
the perimeter membrane (Futter et al., 2001). Annexin 1 was found on the MVB 
membrane and phosphorylated upon EGF stimulation (Futter et al., 1993). It is 
presently unknown how phosphorylation regulates the localization and functions of 
annexin 1. Nevertheless, annexin 1 was found to accumulate in ILVs and knockdown 
of annexin 1 abolished inward vesiculation and caused a minor delay in EGFR 
degradation (White et al., 2006). This suggests that it is not essential for EGFR 
































Fig. 1.5 Schematic diagram of receptor endocytosis 
EGF-induced endocytosis of EGFR can occur through either the clathrin-dependent or 
–independent pathways. Following endocytosis, the receptors are sorted at the early 
endosomes, whereby receptors targeted for degradation are sequestered into the 
intraluminal vesicles (ILV) of multivesicular bodies (MVB), mediated by the ESCRT 
complexes, while certain EGF/EGFR complexes are recycled back to the plasma 
membrane. The receptors in the ILV are subsequently degraded by the hydrolytic 
enzymes from the lysosomes that fused with the MVBs. In addition, endosomal 
trafficking is regulated by a group of small GTPases of the Ras family and every 
endosomal compartment in the endocytic pathway is marked by a specific GTPase. 
Rab5 is associated with the early endosomes, Rab4 resides on the recycling 
endosome, Rab11A marks the endosomal recycling compartment and Rab7 is found 










1.6     Receptor recycling    
  At the early endosomes, some of the endocytosed EGFRs are recycled back to 
the plasma membrane instead of being targeted for degradation. The criteria for the 
selection of receptors which are to be recycled back to the plasma membrane are still 
currently unclear. Nonetheless, not only does an unbound receptor get recycled (in the 
case of constitutive recycling), EGF-bound EGFR has been shown to undergo 
recycling as well (Sorkin et al., 1991a). EGFR recycling occurs via two pathways, 
where EGFR can travel through a rapid or a slow recycling route back to the plasma 
membrane. The rapid recycling pathway refers to the generation of recycling 
endosomes from the early endosomes or an earlier stage in the endocytic pathway. 
Therefore, the distance the recycling endosomes have to travel back to the plasma 
membrane is shorter. On the other hand, the slow recycling pathway has slower 
kinetics and it involves the transport of receptors from the early endosomes to a 
juxtanuclear, endocytic recycling compartment (ERC) where recycling endosomes 
emanate from. The presence of EGFRs in these pathways is evident by the co-
localization of EGFR with the constitutively recycled transferrin receptors in the 
ERC, early and recycling endosomes. Proteins that were implicated in the modulation 
of recycling include PKC-δ, calmodulin and calcium-modulating cyclophilin ligand 
(CAML) (Llado et al., 2008; Tran et al., 2003).     
 
1.7    Endosomal signaling 
  EGF-induced endocytosis of EGFR leads to the dramatic decrease in the 
number of activated receptors at the cell surface and within the cell, a phenomenon 
referred as receptor downregulation. This process results in the termination of plasma 




thought to be an important negative regulatory mechanism that regulates the duration 
and intensity of EGFR signaling. However, this school of thought is slowly becoming 
obsolete as accumulating evidence argues for the hypothesis that endocytosed EGFRs 
are capable of signaling from the endosomes.  
  Activated EGFR, upon EGF stimulation, was shown to remain at the plasma 
membrane for only 5-10 minutes but remains associated at the endosomes for a much 
longer time (1h) (Carpenter, 1987). This suggests that most of the signaling output 
may be generated by the endosomal-associated EGFR rather than the receptors at the 
plasma membrane. The first indication of endosomal signaling came from the 
detection of downstream signaling proteins such Shc, Grb2 and mSOS together with 
activated EGFRs at the early endosomes (Di Guglielmo et al., 1994). Subsequently, 
another study reported that continuous signaling of EGFR from the plasma membrane 
in the absence of clathrin-dependent endocytosis, which was caused by the expression 
of a dominant-negative dynamin mutant (K44A), resulted in reduced activity of 
certain downstream effectors, such as MAPK, PI3K and ERK1/2 (Vieira et al., 1996). 
This data implies that certain downstream signaling processes require the 
internalization of EGF/EGFR complexes into endosomes in order to achieve full 
activation. Altogether, these results support the hypothesis that endosomal signaling 
does occur and the types of endosomal signaling can be divided into two groups, 
mainly signaling that can occur at both plasma membrane and endosomes and 
signaling that take place specifically at the endosomes.  
 
1.7.1    Continuous EGFR signaling from endosomes 
  It is important, especially in vivo where ligands are limited and receptors are 




been internalized so as to ensure that sufficient duration and intensity of signaling 
have been attained. This requires the endocytosed EGFR to be active at the 
endosomes. Evidently, the receptors are shown to remain EGF-bound (due to the low 
dissociation rate of EGF from the receptors at the early endosomes), dimerized and 
phosphorylated at the endosomes until the late stages of endocytic trafficking (Sorkin 
et al., 1988). Moreover, all the components of the MAPK signaling pathway, such as 
Ras proteins, Raf, MEK1/2 and ERK1/2 were detected in the endosomes, providing 
convincing evidence that EGFR can continue signaling after endocytosis (Haugh et 
al., 1999).  
   However it has been difficult to verify the necessity of EGFR endocytosis for 
the activation of various downstream substrates of EGFR. In the case of ERK 
activation, there were conflicting data from various studies. Experiments using 
dominant-negative mutants and knockdown of certain accessory proteins involved in 
endocytosis demonstrated the importance of EGFR endocytosis for ERK activation 
(Sigismund et al., 2008; Vieira et al., 1996). Conversely, another study showed that 
EGFR, Shc, c-Cbl, Raf and MAPK were activated to the same extent in CDE-
deficient cells as compared to cells with intact CDE, thus suggesting that CDE is not 
essential for the full activation of MAPK (Galperin and Sorkin, 2008; Johannessen et 
al., 2000). In the case of EGF-induced STAT3 signaling, EGFR endocytosis has been 
shown to be essential. Disruption of CDE by the expression of Amp A1 or Epsin 2a or 
treatment with phenylarsine oxide (PAO), prevented the trafficking of STAT3 from 
the cell membrane to the perinuclear region and inhibited STAT3 DNA-binding 
activity in the nucleus (Bild et al., 2002). The study thus suggests that STAT3 may be 
actively transported through the cytoplasm to the nucleus via EGFR-containing 




endocytosis in EGFR signaling, especially in the case of MAPK signaling. 
Nevertheless, it is suggested that these differences may be attributed to the different 
degradation rates of the receptors in various cell lines and the specific experimental 
conditions.  
 
1.7.2    Endosomal-specific signaling   
    Endosomal signaling is a way of attaining signal diversification and 
specificity. Hence, the ability of EGFR to initiate signaling directly from the 
endosomes is important in this aspect. Several lines of evidence demonstrated the 
signaling capability of endosomal EGFR. EGFR was shown to recruit and interact 
with Grb2 at the endosomes, thereby indicating the endosomal signaling potential of 
EGFR (Sorkin et al., 2000). Another study provided evidence of endocytosed EGFR 
signaling through the usage of reversible EGFR kinase inhibitor (AG1478) and EGFR 
recycling inhibitor, monensin. EGF-bound inactive receptor (inactivated by the kinase 
inhibitor) was induced to undergo endocytosis and the endocytosed EGFR was 
reactivated by washing out the inhibitor. In turn, the reactivated receptor was able to 
propagate sufficient signaling from the endosomes, which led to cell proliferation and 
survival (Wang et al., 2002). Apart from having endosomal signaling capability, the 
signaling pathways initiated by the endosomal EGFR are found to differ from those 
elicited at the plasma membrane. This is supported by observations of certain 
signaling molecules such as Eps8, associating with the endosomal EGFR and not with 
the plasma membrane EGFR (Burke et al., 2001). Evidently, specific signaling 
complexes can be assembled at the endosomal membrane which supports certain 
signaling cascades that cannot occur or occur with low efficiency at the plasma 




endosomes is an example of a specialized signaling endosome. APPL 1/2 (adaptor 
protein, phosphotyrosine interaction, PH domain and leucine zipper-containing 1/2) 
are Rab5 effectors that are recruited by Rab5 to a subpopulation of early endosomal 
antigen 1 (EEA1) negative endosomes (Miaczynska et al., 2004). These endosomes 
are regulated by phosphatidylinositol 3-phosphate (PI3P), as the production of PI3P 
causes APPL to dissociate and recruits EEA1 onto the endosomes. In addition, APPL-
endosomes were also found to contain EGF-bound EGFR and are essential for Akt 
and MAPK signaling (Zoncu et al., 2009). It is thus suggested that EGFR residence 
time in the APPL-endosomes is controlled by APPL and this in turn may affect the 
intensity of MAPK signaling.        
 
1.8 FYVE domain-containing proteins 
A group of proteins that are also implicated in EGFR trafficking and signaling 
are the FYVE domain-containing proteins. These proteins are characterized by their 
FYVE domain, which specifically bind to PI3Ps (Sankaran et al., 2001). There are 
more than 25 FYVE domain-containing proteins expressed in the mammalian cell 
(Hayakawa et al., 2007). Relatively little is known about the exact functions of the 
majority of the FYVE domain proteins but from the available information gathered, 
these proteins have a diverse array of functions. 
 
1.8.1   The FYVE zinc-finger domain 
The FYVE domain was first identified from EEA1. The acronym FYVE is 
derived from the names of the first four proteins known to possess this domain and 
they are Fab1p, YOTB, Vac1p and EEA1. FYVE domain consists of ~80 amino 




(Kutateladze and Overduin, 2001). In addition, it contains a highly conserved 
R(R/K)HHCRXCG motif which surrounds the third and fourth cysteine residues and 
is required for binding. There are also a few hydrophobic residues that are conserved 
among all the FYVE domains (Hayakawa and Kitamura, 2000).  
The crystal structures of the S. cerevisiae Vps27p, Drosophila Hrs, 
Leishmania major Lm5-1, human EEA1 and FYVE domain-containing 27 B protein 
FYVE domain have been solved and have a close resemblance to the zinc-binding 
domains of rabphilin 3A and PKC family proteins (Kutateladze and Overduin, 2001; 
Mao et al., 2000; Misra and Hurley, 1999). All the FYVE domain structures consist of 
two antiparallel β-sheets (β1-β2 and β3-β4) and a α-helix stabilized by the two Zn2+ 
binding clusters. From the crystal structure, β1-strand and Arg220 in β4-strand 
constitute the conserved R(R/K)HHCRXCG motif and the putative PI3P-binding site. 
In addition, an exposed hydrophobic protrusion, that precedes the β1-strand, inserts 
into the bilayer upon binding of the FYVE domain to the PI3P-containing membrane. 
Most recently, it was reported that interactions of FYVE domain proteins, such as 
EEA1, Hrs, Vps27p, with PI3P-containing membranes are regulated by pH (He et al., 
2009). 
 
1.8.2 FYVE domain proteins and membrane trafficking 
As FYVE domain proteins generally localize to PI3P-enriched endosomal 
membranes through their FYVE domain, they are thus implicated in the regulation of 
endocytic trafficking (Kutateladze, 2006). One of the better characterized FYVE 
domain proteins is EEA1. It binds to PI3P via its FYVE domain in the C-terminus and 
interacts with Rab5 at two binding sites, one adjacent to the FYVE domain and the 




EEA1 to the early endosomes and this localization is dependent on PI3K activity. 
EEA1 is found to be the main component in mediating endosome docking and fusion, 
whereby its binding to PI3P regulates endosome tethering while its interaction with 
Rab5 modulates subsequent endosomal fusion (Christoforidis et al., 1999a; Lawe et 
al., 2002). It is thought that EEA1 may aid in the tethering and fusion of Rab5-
containing endosomes through its interactions with endosomal SNARE proteins such 
as syntaxin 6 and syntaxin 13 (McBride et al., 1999; Simonsen et al., 1999).   
Rabenosyn-5 is another FYVE protein shown to be involved in endosomal 
fusion (Nielsen et al., 2000). This protein consists of a central FYVE domain, C2H2-
type zinc finger at the N-terminus and a NPF-containing motif at the C-terminus that 
may bind to epsin-homology domain (EHD) proteins. Similar to EEA1, Rabenosyn-5 
is a Rab5 effector and is recruited to the early endosomes in a PI3K-dependent 
fashion. In addition to its role in endosomal fusion, Rabenosyn-5 and its interacting 
partner, EHD1, are also shown to regulate endocytic recycling in a sequential mode 
(Naslavsky et al., 2004). A few other endocytic pathways that Rabenosyn-5 and 
another of its interacting partner, EHD3, are involved in include early endosome-to-
Golgi transport and hydrolytic enzymes transport from Golgi to lysosomes (Naslavsky 
et al., 2009).  
Rabip4 is a FYVE domain protein and a Rab4 effector. It localizes to EEA1-
marked early endosomes and expression of Rabip4 together with a constitutively–
active Rab4 increases its co-localization with Rab5-marked early endosomes and 
Rab11-marked recycling endosomes. In addition, overexpression of Rabip4 leads to 
the retention of the glucose transporter Glut 1 within the cells, suggesting that it is 
involved in the endosomal trafficking between recycling and early endosomes 




Hrs, which is mentioned in the previous section as part of the ESCRT 0 
complex involved in the sorting of receptors targeted for degradation, contains a 
FYVE domain as well. Other structural domains that Hrs consists of include an N-
terminus VHS domain, two coiled-coil domains and proline/glutamine-rich regions. 
While it has been identified that Hrs FYVE and second coiled-coil domains mediate 
its binding with PI3P, the full-length Hrs was not able to interact with PI3P in vitro, 
suggesting that other proteins may be needed to regulate its association with PI3P 
(Hayakawa and Kitamura, 2000; Raiborg et al., 2001b). Nevertheless, Hrs is localized 
to the early endosomes and MVBs. Its ability to recruit clathrin to the early endosome, 
interact with sorting nexin 1 (SNX1) (an EGFR lysosomal targeting code recognizing 
protein), Eps15 and retain EGFR in the early endosomes upon Hrs overexpression, are 
all indicative of its role in endosomal trafficking of EGFR (Chin et al., 2001; Raiborg 
et al., 2001a; Roxrud et al., 2008). Through regulation of endosomal trafficking of 
receptors, Hrs is able to modulate various signaling pathways. For example, Hrs has 
been demonstrated to act as a positive regulator of insulin and vascular endothelial 
growth factor (VEGF) signaling through its modulation of receptor trafficking. 
Ectopic expression of Hrs resulted in an increase in insulin receptor and VEGF 
receptor numbers as well as their tyrosine phosphorylation levels, which subsequently 
led to the amplification of their downstream signaling. This increase in receptors was 
attributed to the inhibition of Nedd4-mediated VEGF-R2 degradation by Hrs 
(Hasseine et al., 2007).  
On the other hand, a recently identified FYVE domain protein, hLst2, whose 
endosomal localization is highly dependent on its monoubiquitination, has been found 




EGFR signaling while a non-ubiquitinated hLst2 localized to the endosomes and 
promoted EGFR degradation (Mosesson et al., 2009).  
RUFY1 is a FYVE domain protein that interacts with Etk tyrosine kinase. It is 
shown to be tyrosine phosphorylated by Etk while its localization to the endosomes as 
well as its interaction with Etk are both regulated by its phosphorylation (Yang et al., 
2002). Surprisingly, its endosomal localization is not mediated by its FYVE domain 
but by its coiled-coil domain. On the other hand, its FYVE domain alone localizes to 
the plasma membrane. Nevertheless, RUFY1 is able to prevent Etk-induced inhibition 
on EGFR endocytosis. Overexpression of Etk caused an accumulation of EGFR on 
the plasma membrane but this effect was abolished when co-expressed together with 
the FYVE domain of RUFY1 (Yang et al., 2002). This suggests that RUFY1 acts as a 
negative regulator of Etk’s modulation on EGFR endocytosis.    
 
1.8.3 FYVE domain proteins and signal transduction  
The FYVE domain proteins that are involved in signal transduction include 
the Smad anchor for receptor activation (SARA) and Hrs. SARA regulates TGF-β 
signaling by acting as a scaffold protein and ensuring proper subcellular localization 
of the activated receptor-bound complex. Its localization at the early endosomes (via 
its FYVE domain), in concert with its ability to interact with TGF-β receptors and 
Smad proteins makes it an ideal scaffold protein as it helps to concentrate these 
proteins at a specific compartment. Basically, SARA recruits Smad 2 and Smad 3 to 
the internalized TGF-β receptors at the early endosomes where they are 
phosphorylated by the receptors. The phosphorylation of Smad 2/3 allows them to 
form a heteromeric complex with Smad 4 which is subsequently translocated into the 




2005; Tsukazaki et al., 1998). In the aspect of TGF-β signaling, this is a clear 
demonstration of endosomal signaling.  
Besides regulating membrane trafficking, Hrs is also implicated in various 
signal transduction events. Hrs, which was identified as a tyrosine phosphorylated 
protein, was shown to be involved in hepactocyte growth factor (HGF), EGF, platelet-
derived growth factor (PDGF), interleukin-2 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) signaling (Asao et al., 1997; Komada and Kitamura, 
1995; Sasaki and Sugamura, 2001). In addition, Hrs knockout cells have decreased 
responses to TGF-β/activin stimulation, indicating its role in TGF-β signaling. 
Surprisingly, Hrs is also able to bind to Smad 2 via its C-terminus and cooperate with 
SARA in the recruitment of Smad 2 to the TGF-β/activin receptors for signaling 
initiation (Miura et al., 2000). Proline-, glutamic acid-, and leucine-rich protein-1 
(PELP1) is a protein that functions as a coactivator in estrogen receptor (ER) 
signaling. However its ability to interact with Hrs allows PELP1 to be recruited to the 
early endosomes where it activates MAPK signaling in an EGFR-dependent but 
estrogen receptor-independent manner (Rayala et al., 2006). This demonstrates signal 
diversification resulting from the targeting of signaling proteins to a specific 
compartment other than its usual location within the cell.  
 
1.8.4 FYVE domain proteins that have enzymatic activity 
On top of their PI3P-binding capability, certain FYVE domain proteins 
possess enzymatic activity as well. MTM1-related protein-3 (MTMR3), MTMR4 and 
PIKfyve are FYVE domain-containing enzymes. MTMR3 and MTMR4 belong to the 
myotubularin (MTM1) family of proteins and function as dual specificity 




FYVE domain of MTMR3 does not bind PI3P while its PH-GRAM domain is able to 
bind PI5P instead (Lorenzo et al., 2005). On the other hand, MTMR4 localizes to 
endosomal structures marked by EEA1 and Hrs. Though MTMR4 is demonstrated to 
reduce endosomal PI3P level, it is still able to inhibit EGFR degradation upon 
overexpression. In contrast, a mutation in the FYVE domain of a phosphatase-inactive 
MTMR4 mutant abolished this effect (Lorenzo et al., 2006). PIKfyve is a 
phosphoinositide 5-kinase that generates PI3,5P2. Its localization to the late endocytic 
membranes is mediated by its FYVE domain and is PI3K dependent (Sbrissa et al., 
2002). Besides that, PIKfyve FYVE domain is required for the production of 
endosomes with normal morphology (Ikonomov et al., 2001). 
      
1.8.5 FYVE domain proteins and cytoskeleton regulation  
A few FYVE domain proteins are able to regulate actin cytoskeleton. Fgd1, 
belonging to the faciogenital dysplasia gene family of proteins, is a guanine-
nucleotide exchange factor (GEF) that activates Rho GTPase, CDC42. This protein is 
composed of a Dbl homology (DH) domain (responsible for the GEF activity), two 
pleckstrin homology (PH) domains and a FYVE domain (Pasteris et al., 1994). The 
functions of Fgd1 include the induction of actin polymerization via Rho GTPase 
activation and activation of c-Jun N-terminal kinase signaling that leads to cell growth 
and differentiation (Olson et al., 1996). Fgd2, another member of the family, is 
expressed in antigen presenting cells and has similar functions as Fgd1. This protein is 
localized to the membrane ruffles as well as the early endosomes. However, the 
endosomal localization of Fgd2 was not mediated by its FYVE domain, though its PH 
domain was responsible for its localization to the membrane ruffles (Huber et al., 




filopodia-like microspikes through direct activation of CDC42 and lamellipodia 
through the indirect activation of Rac small G protein (Ikeda et al., 2001; Kim et al., 
2002). It is made up of a F-actin filament-binding domain (FAB), a DH domain, two 
PH domains and a FYVE domain. The FYVE domain, together with the PH and DH 
domains were shown to be required for the lamellipodia formation whereas the FAB 
is needed for the microspikes formation (Kim et al., 2002). This suggested that the 
FYVE domain may function to target Frabin to a specific actin structure in the plasma 
membrane that contains Rac instead of CDC42.  
 
1.9       Endofin 
Endofin is an ubiquitously expressed protein with a FYVE domain in the 
centre, followed by a putative Smad binding domain (SBD) and a canonical type I 
serine/threonine protein phosphatase catalytic subunit (PP1c) binding site (PBD) (Fig. 
1.9). It is predominantly localized at EEA1 marked-early endosomes. This 
localization is mediated by the binding of its FYVE domain to the PI3P on the 
cytosolic part of the endosomal membrane and is dependent on PI3K activity. Unlike 
other FYVE proteins such as EEA1 and Hrs that self-associate to form a dimer or a 
hexamer respectively (Callaghan et al., 1999; Pullan et al., 2006), Endofin does not 
associate with itself.  
The first hint on the function of Endofin came from the overexpression of 
Endofin in A431 and COS7 cells that resulted in aggregated/fused or enlarged 
vesicular structures containing EEA1 and transferrin receptors. This indicated that the 
structures were derived from early and recycling endosomes and suggests that 
Endofin may be involved in the endosome fusion during endosomal trafficking. In 




degradation (Seet and Hong, 2001). This indirectly implicates Endofin in the 
regulation of EGFR degradation through its regulation of the endosomal transport 
between the early endosomes and the lysosomes. Although Endofin resembles SARA 
structurally, a FYVE protein involved in TGF-β signaling regulation, it is neither able 
to interact with SARA or Smad2, nor has any effect on TGF-β induced transcriptional 
activity (Seet and Hong, 2001).  
However, one study reported conflicting results, whereby Endofin was 
demonstrated to interact with not only SARA, but with SMAD4, ALK5 (TGF-β 
receptor), ALK3 and ALK6 (BMP receptors), ALK4 (activin receptor) and ALK1 
(TGF-β/BMP receptor) as well. Furthermore, knockdown of Endofin attenuated TGF-
β induced transcription of genes, such as PAI-1, p21CIP1 expression, and delayed 
apoptosis. Smad2 phosphorylation and Smad2-Smad4 complex formation were also 
affected in the absence of Endofin (Chen et al., 2007b). These results suggested that 
Endofin facilitates TGF-β signaling by bringing Smad4 to the vicinity of TGF-β 
receptor complex, thus promoting the formation of Smad4-Smad2 complex.  
Interestingly, another study implicated Endofin in the regulation of bone 
morphogenetic protein (BMP) signaling pathway where interactions between Endofin 
and unphosphorylated Smad1 and PP1c, through its SBD and PBD domain were 
detected respectively. Phosphorylation of ALK3 and Smad1 in response to BMP2 was 
reduced during overexpression and knockdown of Endofin respectively. In addition, 
mutations in Endofin’s FYVE and SBD domains decreased BMP signaling while 
mutation of PBD domain enhanced it (Shi et al., 2007). More recently, the expression 
of a mutant Endofin (F872A), which disrupts its interaction with PP1c, was shown to 
sustain BMP type I receptor signaling and this led to an increase in bone formation 




anchor which exerts a positive and negative regulation on BMP signaling. Yet again, 
these results contradicted with the previous study as it demonstrated that Endofin has 
no effect on BMP signaling in their knockdown experiments (Chen et al., 2007b). The 
reasons for the discrepancy in the results are unclear. Nonetheless this evidently 
indicates that further investigation on the exact role that Endofin plays in both TGF-β 
and BMP signaling is required.  
Another interesting protein that was found to interact with Endofin is TOM1, a 
protein identified from a yeast two-hybrid screen with the carboxyl terminal half of 
Endofin as bait. It was shown to be recruited together with clathrin from the cytosol to 
the early endosomes by Endofin, thus suggesting that Endofin-TOM1 interaction is 
essential for endosomal clathrin recruitment (Seet and Hong, 2005; Seet et al., 2004). 
TOM1 is closely related to the GGA proteins in terms of its structural organization, 
which is composed of a VHS (VPS-27, Hrs and STAM) domain, GAT (GGA and 
TOM1) homology domain and a GAE (gamma-adaptin ear) domain. The GGA 
proteins are mainly localized at the cytosolic part of the trans-Golgi network while 
some are found at the endosomes (as in the case of TOM1). The VHS domain 
recognizes sorting signals present in the cytosolic tails of certain receptors and 
thereby directs their sorting to vesicles targeted for the endosomal/lysosomal pathway 
(Bonifacino, 2004). On top of this, TOM1 interacts with ubiquitin chains, thus 
indicating its ability to bind polyubiquitinated proteins (Yamakami et al., 2003). 
Based on these data, one could hypothesize that TOM1 binds to polyubiquitinated 
proteins (eg. receptors) targeted for lysosomal degradation in the early endosomes and 
sorts them from those that are to be recycled. Conversely, it is proposed that Endofin 
controls this process by regulating the recruitment of TOM1 and its associated 







Fig. 1.9  Schematic representation of the various domains and interacting 
partners of Endofin  
 
The domains that Endofin possesses include the FYVE domain, a Smad binding 
domain (SBD) and a canonical type I serine/threonine protein phosphatase catalytic 
subunit (PP1c) binding site (PBD). In addition, the two binding sites for TOM1 have 
been mapped out. A number of tyrosine and serine residues were also identified 
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1.10     Research objectives 
Endofin is a newly characterized protein that has little reported functions. 
With only a few studies of its involvement in signaling pathways such as TGF-β and 
BMP signaling, its role in cell signaling regulation is not well understood. In EGFR 
signaling, Endofin was discovered to be a novel tyrosine phosphorylation target 
within this pathway (Chen et al., 2007a). It was shown to be tyrosine phosphorylated 
and its localization to early endosomes (indicated by punctate structures in 
immunofluorescence studies) exhibited an outward radiating pattern from the cell’s 
perinuclear region upon EGF stimulation. These two observations could be blocked 
by Iressa, a highly selective EGFR inhibitor, indicating that these two processes are 
EGFR-dependent. Further investigation on the roles that Endofin and its 
phosphorylation play in the regulation of EGFR signaling is thus essential in order to 
gain a deeper understanding of its functionality within this signaling pathway. In this 
study, elucidation of the molecular signaling events associated with Endofin during 
EGF/EGFR signal transduction, is aimed to be achieved through the:  
- characterization of EGF-induced tyrosine phosphorylation of Endofin and  




















Materials and Methods 
2.1 Chemicals and reagents  
All chemicals used for buffers and gels were purchased either from Sigma, 1st 
Base (Selangor Darul Ehsan, Malaysia) or Bio-rad (Hercules, CA), unless otherwise 
stated. Lipofectamine™ 2000 and Opti-MEM® were supplied by Invitrogen 
(Carlsbad, CA). Active EGF receptor kinase, U1026 and Rapamycin were obtained 
from Cell Signaling Technology (Beverly, MA). Wortmannin, TGF-α, TGF-β1, IGF-
1 and EGF were supplied by Sigma Aldrich (St. Louis, MO) while bFGF was from 
Chemicon (Temecula, CA). Cycloheximide was purchased from Santa Cruz Biotech 
(Santa Cruz, CA). ADZ0530 and Iressa were kind gifts from AstraZeneca 
(Washington DC, USA). MTS assay was obtained from Promega (San Luis, CA). 
Endofin-specific siRNA and siRNA targeting its 3’UTR were purchased from 
Invitrogen (Carlsbad, CA) and the siRNA sequences are as follows: 
Endofin-specific - AAAGCUAGCCGCAAGCCAUUCAUGG 
                            - AAUUCAACCAUAUCAGUGUCAAUGG 
 3’UTR               - CCUUAUGAAGGAAAUAUCUGCUUUG  
 
2.2 Antibodies  
 Anti-myc, anti-pAkt (pS473), anti-Akt (5G3) and anti-pMAPK were obtained 
from Cell Signaling Technology (Beverly, MA). Horseradish peroxidase-conjugated 
anti-phosphotyrosine (PY20H), anti-EGFR, anti-Erk1, anti-c-Cbl and anti-PI3 Kinase 
(p110α) were purchased from BD BioSciences (San Jose, CA). Anti-EGFR used for 
immunofluorescence was obtained from Upstate Biotechnology (Lake Placid, NY). 




Abcam (Cambridge, UK) while anti-myc, anti-Src, anti-pSrc, anti-HA, anti-Eps15, 
anti-α-adaptin and horseradish peroxidase-conjugated anti-actin were from Santa 
Cruz Biotech (Santa Cruz, CA). Anti-mouse and anti-rabbit agarose were obtained 
from Sigma Aldrich (St. Louis, MO). Anti-mouse and anti-rabbit conjugated to 
flurophores Alex Fluor 488 and 568 were obtained from Molecular Probes 
(Invitrogen). With assistance from NeoMPS SA (Strasbourg, France), we produced a 
rabbit anti-Endofin polyclonal antibody raised against a peptide (amino acids 190-
205, NDTSSELQNREIGGIK) in the N-terminus of human Endofin. 
 
2.3 Plasmid constructs 
pMyc-EGFR and myc-tagged Endofin-WT plasmids were kind gifts from Dr 
Graeme Guy and Professor Wanjin Hong (Institute of Molecular and Cell Biology) 
respectively while pcDNA-EGFR was from Dr Pier Paolo Di Fiore (Istituto FIRC di 
Oncologia Molecolare). HA-tagged dynamin I (K44A) mutant was from Dr Lois 
Greene (NHLBI, Bethesda), while GFP-Rab4, GFP-Rab5, GFP-Rab7, and GFP-
Rab11 were obtained from Dr Juan Bonifacino (NICHD, Rockville). Wild-type Src 
(Src WT) and dominant-negative Src (Src DN) mutant were kind gifts from Dr Sara 
Courtneidge. The plasmids received were transformed into E. coli cells and plated on 
LB plates in order to obtain single clones. A few colonies were inoculated into 200 
mL of LB culture and incubated with shaking at 37°C overnight. Plasmid DNA were 
extracted from the bacterial culture using PureLink™ HiPure Filter Plasmid Maxiprep 
kit (Invitrogen) according to the manufacturer’s instructions. Extraction of the 
plasmids is based on the usage of high salt concentration to precipitate out the 




plasmid DNA in solution. These precipitates were subsequently cleared away and the 
plasmid DNA were purified out with washing and elution.  
 
2.4 Site-directed Mutagenesis  
Endofin YÆF mutants were generated by site-directed mutagenesis using the 
QuikChange mutagenesis kit (Stratagene, La-Jolla, CA). In brief, complementary 
primers with the point mutations were designed and used to amplify the original 
plasmid construct according to the manufacturer’s instruction. The methylated wild-
type plasmid was digested away from the non-methylated mutation-containing 
plasmid with the restriction enzyme DpnI at 37ºC for 1 hour. The mutant plasmids 
were then transformed in to competent E. coli and the plasmids extracted from the 
clones were sequenced for the confirmation of the mutations.    
 
2.5 Cell culture   
Human embryonic kidney (HEK) 293 and epithelial carcinoma A431 cell lines 
were obtained from the American Type Culture Collection (Rockville, MD) and was 
cultured in Dulbecco’s MEM supplemented with 10% FBS (Hyclone, ThermoFisher, 
Waltham, MA), 1% penicillin/streptomycin. Xenograft-derived breast cancer cell line, 
MCF10AT1K, was obtained from Dr. Fred Miller at the Barbara Ann Karmanos 
Cancer Institute (Detroit, MI) and maintained in DMEM/F-12 supplemented with 5% 
horse serum, 1% penicillin/streptomycin, 10 μg/ml insulin, 20 ng/ml EGF, 0.5 μg/ml 
hydrocortisone, and 100 ng/ml cholera toxin. Hela Tet-On© was obtained from 
Clontech Laboratories (Mountain View, CA) and cultured in RPMI-1640 with 10% 




were incubated at 37ºC in a humidified atmosphere containing 5% CO2 and serum 
starved for 16 hours before growth factor stimulation experiments.  
 
2.6       Transfection 
For DNA transfection, cells were seeded at about 80-90% confluency the day 
before transfection. On the day of transfection, the medium incubating the cells was 
replaced with fresh complete growth medium, while the indicated plasmids and 
Lipofectamine™ 2000 were diluted in Opti-MEM medium (DNA: Lipofectamine = 1 
μg:3 μl). Diluted DNA and Lipofectamine were then mixed together and incubated at 
room temperature for 20 minutes prior to adding to the cells. After incubation for 4-6 
hours, the transfection medium was replaced with fresh complete medium. 
Transfected cells were incubated for 24-48 hours at 37ºC to allow for protein 
expression before subjecting them to overnight serum-starvation or harvesting them. 
As for siRNA transfection, the procedure is similar to DNA transfection except that 
the final concentration of siRNA used was 20 nM.  
 
2.7       Cell lysis 
Following overnight serum-starvation, cells were stimulated with 50 ng/ml of 
EGF at 37ºC for the indicated times and when specified, pretreated with 1 µM of 
Wortmannin, ADZ0530, U1026, 1 nM of Rapamycin, 10 µM of Iressa, or 10 μg/mL 
of cycloheximide for 1 hour before EGF stimulation. For protein extraction, cells 
were washed twice with ice-cold PBS before lysis with non-ionic denaturing (NID) 
lysis buffer [50 mM Tris-HCl (pH 7.5), 0.5% Triton X-100, 0.5% Igepal, 150 mM 
NaCl, 1 mM EDTA, 50 mM NaF, 1 mM Na3VO4 and protease inhibitors]. The cells 




from the lysates by centrifuging them at 14,000 rpm for 15 minutes at 4ºC. Protein 
concentration was then estimated using a Bicinchoninic Acid Assay kit (Pierce 
Biotechnology, Rockford, IL) and measuring the absorbance at a wavelength of 550 
nm with a microplate reader (Tecan Infinite M200, Tecan).      
 
2.8       Subcellular fractionation  
Cells seeded onto 15 cm plates were scrapped down with 1 ml of fractionation 
buffer [10 mM Tris-HCl (pH 7.4), 1 mM EGTA, 1 mM EDTA, 2 mM MgCl2, 10 mM 
KCl, 50 mM NaF, 1 mM Na3VO4 and protease inhibitors] using a rubber policeman, 
put on ice for 30 minutes to allow for swelling of cells, followed by homogenization 
with 15 strokes of the Dounce homogenizer. The homogenate was layered onto 
fractionation buffer containing 1 M sucrose and spun at 1500g, 4ºC for 10 minutes. 
The supernatant of the topmost layer was removed and further centrifuged at 
150,000g, 4ºC for 30 minutes in an ultracentrifuge (Himac CP90WX, Hitachi). The 
supernatant of this centrifugation was then used as the non-nuclear intracellular 
fraction. The pellet was then resuspended in fractionation buffer containing 1% 
Nonidet-P40, 1% SDS and 1% Triton-X and centrifuged at 150,000g, 4ºC for 30 
minutes. The supernatant of this centrifugation was used as the plasma membrane 
fraction. 
 
2.9  Immunoprecipitation  
0.5-1 mg of cell lysates were incubated overnight with end-to-end rotation at 
4ºC with the specific antibodies and anti-mouse or anti-rabbit IgG-agarose beads. The 




buffer. After washing, 2x Laemmli buffer was added to the immunoprecipitates and 
boiled at 95ºC for 5 minutes. The eluted proteins were then subjected to SDS-PAGE. 
 
2.10 Immunoblotting 
Cell lysates were resolved by SDS-PAGE using the Bio-Rad Mini-Protean II 
system. The stacking gel consists of 4% acrylamide/Bis (30:1), 0.125 M Tris-HCL 
(pH 6.8), 0.1% SDS, 0.1% (w/v) ammonium persulfate and 0.01% (v/v) TEMED. The 
resolving gel was composed of 7.5-12% acrylamide/Bis (30:1), 0.375 M Tris-HCL 
(pH 8.8), 0.1% SDS, 0.1% (w/v) ammonium persulfate and 0.01% (v/v) TEMED. 
Equal volume of 2x Laemmli buffer was added to the 50-100 μg of cell lysates and 
boiled at 95ºC for 5 minutes before loading into the wells. The electrophoresis buffer 
was made up of 25 mM Tris, 192 mM glycine and 0.1% SDS. After the proteins were 
resolved, they are transferred from the gel to a PVDF membrane (Bio-rad) with Bio-
Rad Trans-Blot system for 1 hour, 4ºC at 100 V in a transfer buffer (25 mM Tris, 192 
mM glycine, 10% SDS and 20% methanol). Membranes were blocked in PBST (PBS 
containing 0.1% Tween 20) containing 1-5% BSA or milk for 1 hour at room 
temperature or overnight at 4ºC and incubated with primary antibodies [anti-Endofin 
(1:1000), anti-pAkt (S473) (1:1000), anti-Akt (1:1000), pMAPK (1:1000), Erk1 
(1:5000), EGFR (1:1000), Myc (1:1000), Actin-HRP (1:2000), anti-Na+/K+ ATPase 
(1:1000), anti-PI3K (1:250), anti-pSrc (1:1000), anti-Src (1:1000), anti-Rab5 
(1:1000), anti-EEA1 (1:1000), anti-Eps15 (1:1000), anti-c-Cbl (1:1000), anti-α-
adaptin (1:1000), PY20H (1:1000)] either for 1 hour at room temperature or overnight 
at 4ºC. They were then washed with PBST for 3 times, 5 minutes each and incubated 
with secondary antibody linked to horseradish peroxidase for 1 hour. After secondary 




before the immunoreactive bands were detected using the enhanced 
chemiluminescence (ECL) detection reagents (GE Healthcare, Amersham). Band 
intensities were measured using a densitometry program, called ImageQuant from GE 
Healthcare. The detection of the bands is based on the emission of light by the HRP-
catalyzed oxidation of luminol which is captured on the X-ray film (Konica).  
 
2.11 In vitro kinase assay  
500 μg of cell lysate was used for immunoprecipitation with anti-myc 
antibodies. After incubating overnight at 4ºC with end-to-end rotation, the 
immunoprecipitates were washed thrice with NID lysis buffer and once with cold 
kinase buffer. An in vitro kinase reaction was set up with the addition of 40 μl kinase 
buffer [10 mM Tris (pH 7.4), 150 mM NaCl, 10 mM MgCl2 and 0.5 mM DTT], 200 
μM ATP and 50 ng of active EGF receptor kinase to the immunoprecipitates and 
incubated on a shaker at 30°C for 30 minutes. The reaction was terminated by 
washing the beads twice with NID lysis buffer and eluting the proteins by boiling 
them with 2x Laemmli buffer at 95°C for 5 minutes. The eluted proteins were then 
resolved by SDS-PAGE and probed with PY20H antibody to detect for the presence 
of phosphorylation.  
 
2.12 Immunofluorescence  
Cells were grown on cover slips in 6-well plates till 60% confluent before 
subjecting to various treatments. They were then fixed with 4% paraformaldehyde in 
PBS at room temperature for 15 minutes and washed with 100 mM of glycine in PBS 
for 3 times before permeabilized with 0.5% Triton X-100 for 5 minutes at 4ºC. After 




overnight at 4ºC [Anti-Endofin (1:50), anti-EGFR (BD) (1:40), anti-EGFR (Upstate) 
(1:35), anti-myc (1:50), anti-EEA1 (1:50) and anti-CD63 (1:50)]. This was followed 
by secondary antibodies conjugated to Alex Fluor 488 or 568 (Invitrogen, Molecular 
Probes, CA) incubation at 1:2000 dilutions for 1 hour at room temperature. The cells 
were washed with PBST for 3 times, 5 minutes each after the incubation. The nuclei 
of the cells were counterstained with 4,6-diamidino-2-phenylindole (DAPI) at 
1:10,000 dilution for 1 minute. Cover slips containing the cells were then mounted 
onto glass slides with the addition of Prolong anti-fade reagent (Invitrogen, Molecular 
Probes) and sealed with transparent nail polish. Analyses were made using the laser 
confocal microscope, Olympus FluoView™ FV500 (Olympus Corporation) with a 
60X oil immersion objective. The Olympus Fluo View™ FV10ASW-1.5 software 
was used to capture and analyze the images, including the measurement of Pearson 
coefficients of co-localization.   
Pearson's correlation coefficient is calculated according to the equation: 
 
where S1 is the signal intensity of pixels in the first channel and S2 is the signal 
intensity of pixels in the second channel. The values S1 (average) and S2 (average) 
are the average values of pixels in the first and second channel, respectively. The 
resulting Pearson coefficient values range from -1 to 1, whereby -1 representing a 








2.13 Proliferation assay   
Transfected cells were seeded into four 96-well plates, with 1000 cells per 
well. After the cells have adhered onto the well surface, the medium was replaced 
with low serum medium (1% serum) and incubated overnight. Next day, all four 
plates of cells were stimulated with 50 ng/ml of EGF and 20 μl of MTS reagent was 
added to each well (containing 100 μl of medium) of 1 plate. The cells were incubated 
at 37ºC for 1 hour and the absorbance of the soluble formazan product produced by 
the mitochondrial dehydrogenase enzyme of viable cells through their reduction of the 
MTS tetrazolium compound were determined at a wavelength of 492 nm using the 
multimode microplate reader (Tecan Infinite M200, Tecan). This absorbance reading 
was taken as day zero reading. The MTS assay was repeated daily on the remaining 
plates of cells for the next three consecutive days. The average absorbances of the 
triplicates were then plotted into a graph for analysis.  
For Endofin knockdown cell proliferation assay, Endofin siRNA was 
transfected into the cells by the reverse transfection method. In brief, siRNA and 
Lipofectamine were diluted in Opti-MEM and mixed for 20 minutes in the 96-well 
plates. The cells were trypsinized and 1000 cells added directly into each well of the 
96-well plates containing the siRNA and Lipofectamine mixture. They are incubated 
overnight at 37ºC before the medium was replaced with serum-free medium to starve 
the cells for 16 hours. After which 50 ng/ml of EGF was added to the cells and MTS 










3.1       Characterization of Endofin phosphorylation 
3.1.1 Tyrosine phosphorylation of Endofin occurs upon TGF-α stimulation and 
is dependent on EGFR activation 
 
Although Endofin was identified as a novel tyrosine phosphorylation target in 
EGF signaling pathway previously (Chen et al., 2007a), the possibility that Endofin 
phosphorylation can be induced by growth factors other than EGF has not been 
explored. To determine the effect of other growth factors on Endofin phosphorylation, 
MCFAT1K cells were stimulated with various growth factors for 15 minutes and the 
phosphorylation of immunoprecipitated Endofin were detected with anti-
phosphotyrosine antibodies conjugated to Horseradish Peroxidase (PY20H). The 
activation of ERK, as shown by the detection of pMAPK in Figure 3.1.1A, in all the 
samples indicated that the cells were responsive to basic fibroblast growth factor 
(bFGF), insulin growth factor-1 (IGF-1) and transforming growth factor-α (TGF-α). 
However, no phosphorylation of Endofin could be observed upon stimulation by IGF-
1 and bFGF, which activate tyrosine kinase receptors, IGFR and FGFR respectively. 
This indicated that tyrosine phosphorylated Endofin does not act within IGF-1 and 
bFGF signaling pathways at least at the timepoint studied. Endofin was found to be 
phosphorylated upon stimulation by TGF-α, though its phosphorylation level was 
much lower as compared to that of EGF-induced.  
TGF-α shares a 40% sequence homology with EGF and is a known ligand of 
EGFR. Although EGF and TGF-α bind to the same receptor, they initiate different 
cellular outcomes (Ellis et al., 2007). Given that TGF-α activates EGFR and 




α-induced Endofin phosphorylation may be exerted through EGFR as well. To 
confirm this, MCFAT1K cells were pre-treated with Iressa, an inhibitor of EGFR 
tyrosine kinase activity, for 1 hour before stimulation with either EGF or TGF-α and 
the phosphorylation levels of Endofin and EGFR were determined with PY20H. As 
seen in Figure 3.1.1B, EGFR was activated upon TGF-α stimulation and its 
phosphorylation level was much lower compared to EGF-induced phosphorylation. 
This correlated with EGF/TGF-α-induced Endofin phosphorylation levels. The lower 
TGF-α-induced EGFR phosphorylation level may be attributed to the lower affinity 
of TGF-α for EGFR, which has been shown to dissociate from the receptors in the 
acidic environment of the early endosomes, resulting in receptor dephosphorylation 
and recycling back to the plasma membrane (French et al., 1995). Nevertheless, Iressa 
efficiently abolished EGF/TGF-α-induced EGFR phosphorylation together with 
Endofin phosphorylation (Fig. 3.1.1B). This indicates that TGF-α-induced 












Fig. 3.1.1 Endofin is phosphorylated upon TGF-α stimulation and requires 
EGFR activity  
 
(A) Serum-starved MCFAT1K cells were either unstimulated or stimulated with 50 
ng/mL of EGF, bFGF, IGF-1 and TGF-α for 15 mins at 37°C and harvested. Endofin 
was immunoprecipitated from the lysates and its phosphorylation level analyzed with 
PY20H. (B) Serum-starved MCFAT1K cells were either untreated or pre-treated with 
10 μM of Iressa for 1 h and stimulated with 50 ng/mL of EGF or TGF-α  for 15 mins 
at 37°C before harvesting. Immunoprecipitated Endofin and EGFR phosphorylation 






3.1.2 TGF-β does not induce tyrosine phosphorylation of Endofin 
 
 One of the signaling pathways in which Endofin was shown to be involved in 
is TGF-β signaling. In this pathway, Endofin interacts with Smad4 and brings it to the 
receptor vicinity, thereby promoting the formation of R-Smad-Smad4 complex and 
facilitating TGF-β signaling (Chen et al., 2007b). However it has never been shown 
whether Endofin is tyrosine phosphorylated upon TGF-β stimulation. To do this, 
MCFAT1K cells were stimulated with TGF-β for 15 minutes and tyrosine 
phosphorylation of immunoprecipitated Endofin was determined with PY20H. This 
particular stimulation timepoint is chosen for the study as TGF-β is shown to activate 
MAPK pathway in Mv1Lu and 3T3-Swiss cells between 5-30 minutes (Lee et al., 
2007). Evidently, Endofin was not phosphorylated upon TGF-β stimulation (Fig. 
3.1.2). This shows that tyrosine phosphorylation is not required for its function as a 
scaffold protein in TGF-β signaling.       
 
 
Fig. 3.1.2 Endofin is not phosphorylated upon TGF-β stimulation  
Serum-starved MCFAT1K cells were either unstimulated or stimulated with 50 
ng/mL of EGF and TGF-β for 15 mins at 37°C and harvested. Endofin were 





3.1.3  Endofin phosphorylation correlates closely to EGFR activity 
 
For the characterization of Endofin phosphorylation, studies of EGF-induced 
tyrosine phosphorylation kinetics of Endofin were conducted in various cell lines. 
Phosphokinetics of Endofin was first determined in MCF10AT1K breast cancer cell 
line, which we have previously demonstrated to display “normal” EGFR kinetics 
following EGF stimulation, i.e. transient activation followed by modulation within 30 
minutes (Choong et al., 2007). Cells were subjected to EGF stimulation for the 
indicated times and the tyrosine phosphorylation levels of immunoprecipitated 
endogenous Endofin and EGFR were determined by probing with PY20H. Tyrosine 
phosphorylation of Endofin was most intense at 15 minutes and started to decrease 
from 20 minutes onwards. These kinetics followed closely to that of EGFR, which 
was most strongly phosphorylated at 10 minutes and started to decease at 15 minutes 
(Fig. 3.1.3A). The close resemblance of the tyrosine phosphorylation kinetics between 
Endofin and EGFR suggests that the phosphorylation of Endofin is tightly coupled to 
that of EGFR. The expression level of Endofin was stable throughout the time course, 
indicating that the modulation of Endofin phosphorylation was not due to protein 
degradation.  In contrast, drastic diminution of EGFR expression was observed at 25 
minutes, presumably due to the well reported ubiquitin-mediated degradation of 
EGFR (Sebastian et al., 2006; Sorkin and Goh, 2008).  
A431 is a human epithelial carcinoma cell line that expresses high level of 
EGFRs. In addition, A431 cells have been reported to have a high degree of EGFR 
recycling which masks the effects of its downregulation (Masui et al., 1993). 
Studying the phosphorylation of Endofin in a system that exhibits insignificant 
downregulation would be interesting, hence a phosphokinetic study was performed in 




A431 cells throughout the entire stimulation period. EGFR levels remained constant 
while its phosphorylation increased progressively throughout the timecourse. 
Conversely, Endofin phosphorylation peaked at 30 minutes, stayed constant till 60 
minutes and decreased by 120 minutes (Fig. 3.1.3B). The drop in Endofin 
phosphorylation in the presence of constant EGFR activity suggests the existence of 
an active phosphatase at work.  
The phosphorylation kinetics study of exogenous Endofin was conducted in 
EGF-responsive Hela cells to determine if it was phosphorylated in the same way as 
the endogenous Endofin. Indeed, the phosphorylation of myc-tagged Endofin 
followed the endogenous Endofin phosphorylation trend in MCF10AT1k cells, with it 
peaking around 5 minutes and modulated within 30 minutes of EGF stimulation (Fig. 
3.1.3C).  
In general, the phosphorylation patterns of Endofin in MCF10AT1K, A431 
and Hela cells were largely similar. The only major difference is in the length of 
Endofin phosphorylation within these cell lines. Phosphorylation of Endofin in 
MCF10AT1K and Hela cells correlates closely with the activity of EGFR and thus 
was rapid and short-lived. On the other hand, Endofin phosphorylation was much 
more prolonged (~up to 60 mins) in A431 cells before diminishing due to an unknown 
mechanism. Overall, Endofin phosphorylation correlates with EGFR activity.   
 








Fig. 3.1.3 Endofin phosphorylation is dependent on EGFR activity 
(A) MCF10AT1K, (B) A431 and (C) Hela cells were serum-starved, stimulated with 
50 ng/mL of EGF for the indicated timepoints and then harvested. Endogenous, myc-
tagged Endofin and EGFR were immunoprecipitated out and their phosphorylation 





3.1.4 Endofin is phosphorylated in the cytosol and clathrin-dependent 
endocytosis is essential for Endofin phosphorylation 
 
 In the IF data reported, punctate structures representing Endofin were shown 
radiating towards the cell periphery, which hinted at the presence of tyrosine-
phosphorylated Endofin in endosomes following EGF treatment (Chen et al., 2007a). 
Since PI3P production is expected to exist at the plasma membrane in addition to the 
endosomes (Lindmo and Stenmark, 2006), there is a possibility of Endofin associating 
with the plasma membrane, where EGFR resides and becomes phosphorylated as 
well. To this end, MCF10AT1K cells were first stimulated over a time course before 
being separated into plasma membrane and non-nuclear intracellular fractions by 
preparative ultracentrifugation. Protein marker for plasma membrane 
(sodium/potassium ATPase) fraction was routinely used to check the quality of the 
preparations (Fig. 3.1.4A). Immunoprecipitation and immunoblotting results of the 
fractions revealed that no Endofin could be detected in the plasma membrane fraction 
within the time frame examined. Most, if not all, of the phosphorylated and non-
phosphorylated Endofin were found within the non-nuclear intracellular fraction. This 
implies that Endofin is not phosphorylated at the plasma membrane. Simultaneously, 
markers of the early endosomes, EEA1 and Rab5 were also present in the non-nuclear 
intracellular fraction where phosphorylated Endofin was detected, thus suggesting the 
co-existence of these proteins in the same compartment within the cell (Fig. 3.1.4A). 
This correlates with the reported localization of Endofin in the early endosomes, as 
reflected by the observation of Endofin’s co-localization with EEA1 in the published 
studies (Chen et al., 2007a; Seet and Hong, 2001).  
Since Endofin phosphorylation coincides closely with EGFR activity and 
occurs within the cytosol, this prompted the question of the effect of EGFR trafficking 




utilized for the internalization of EGFR (Sorkin and Goh, 2008). To ascertain if 
clathrin-dependent endocytosis of EGFR is required for Endofin phosphorylation, two 
approaches were employed to answer this question. The first approach utilized low 
temperature to impede endocytosis of EGFR. It is a generally accepted notion that 
EGF/EGFR complexes are minimally internalized when cells are stimulated at 4°C 
and the activated EGFR remains at the membrane and continues signaling from there. 
Hela cells co-transfected with EGFR and myc-tagged Endofin-WT, were thus 
stimulated with EGF at 4°C and 37°C and the phosphorylation of immunoprecipitated 
Endofin was determined with PY20H. As seen in Figure 3.1.4B, no apparent 
modulation of EGFR was detected in cells stimulated at 4°C even though the 
receptors were clearly activated (as indicated by EGFR phosphorylation). This 
therefore confirmed the absence of EGFR internalization at 4°C. Additionally, EGFR 
activity was unaffected by the low temperature as its phosphorylation levels were 
comparable between 4°C and 37°C. In comparison to cells stimulated at 37°C, 
Endofin phosphorylation was drastically reduced by 6- and 4-fold when stimulated for 
5 and 30 minutes respectively at 4°C (Fig. 3.1.4C). This indicates that EGFR 
internalization is required for Endofin phosphorylation.  
The second approach made use of a dominant-negative dynamin mutant 
(K44A) which has been shown to inhibit clathrin-dependent endocytosis. To assess 
the ability of the dynamin mutant to inhibit EGFR internalization, HA-tagged 
dynamin mutant was co-transfected into Hela cells together with myc-tagged Endofin-
WT and EGFR, stimulated with EGF for 30 minutes and the EGFR level was 
determined. In comparison to the non-dynamin mutant expressing cells, EGFR 
degradation was significantly reduced in the K44A dynamin mutant expressing cells, 




negative dynamin mutant (Fig. 3.1.4D). Hence, the experiment was repeated with the 
EGF stimulation timepoint reduced to 5 minutes as this is the previously observed 
timepoint (Fig. 3.1.3C) which displayed the highest level of Endofin phosphorylation 
in Hela cells. No obvious downregulation of EGFR could be seen in dynamin mutant 
and non-dynamin mutant expressing cells due to the short timepoint studied (5 mins). 
Nevertheless, consistent with Figure 3.1.4B, Endofin phosphorylation in cells 
expressing dynamin mutant (K44A) was also greatly diminished, thereby implying 
that Endofin phosphorylation requires clathrin-dependent endocytosis of EGFR (Fig. 
3.1.4E). In brief, both results support the view of EGFR endocytosis being necessary 
for Endofin phosphorylation.  
 
 
Fig. 3.1.4A Phosphorylated Endofin was detected in non-nuclear intracellular      
compartment  
 
Serum-starved MCF10AT1K cells were stimulated with 50 ng/mL of EGF for the 
indicated timepoints and then harvested. The cell lysates were separated into plasma 
membrane and non-nuclear intracellular fractions. The fractions were analyzed with 
the indicated antibodies while phosphorylation of immunoprecipitated Endofin was 









Fig. 3.1.4B-C Endofin phosphorylation is dependent on EGFR endocytosis 
 
(B) Hela cells co-transfected with EGFR and myc-tagged Endofin-WT were 
stimulated with 50 ng/mL of EGF at 4°C and 37°C for the indicated timepoints before 
they were harvested. Phosphorylation of immunoprecipitated EGFR and Endofin were 
determined with PY20H. (C) Relative intensities of myc-Endofin phosphorylation 










Fig. 3.1.4D-E Endofin phosphorylation requires EGFR clathrin-dependent 
endocytosis  
 
Hela cells co-transfected with or without HA-tagged dynamin mutant (Dyn (K44A)), 
myc-tagged Endofin-WT and EGFR were stimulated with 50 ng/mL of EGF for (D) 
30 mins and (E) 5 mins before harvesting. Whole cell lysates were analyzed with the 
indicated antibodies. Phosphorylation of immunoprecipitated Endofin was determined 





3.1.5 EGF-induced PI3K activity and proper localization of Endofin are     
necessary for its tyrosine phosphorylation  
 
Activation of PI3K in cells stimulated with EGF is a well characterized 
phenomenon in EGFR signaling (Normanno et al., 2006). Being a FYVE domain-
containing protein that binds PI3P, a product of PI3K, suggested that tyrosine 
phosphorylation of Endofin might be dependent on PI3K activity and its localization 
to PI3P-enriched membranes. The localization of many FYVE domain-containing 
proteins is sensitive to the PI3K inhibitor, Wortmannin (Burd and Emr, 1998; Gaullier 
et al., 1999; Gaullier et al., 1998; Patki et al., 1998), which has also been shown to 
cause the redistribution of Endofin to the cytosol (Seet and Hong, 2001). Hence, 
Endofin’s ability to be tyrosine phosphorylated by EGFR in the presence of 
Wortmannin was investigated. This experiment was conducted in A431, 
MCF10AT1K and HEK293 cells co-transfected with EGFR and myc-tagged Endofin-
WT. The cells were either untreated or pre-treated with Wortmannin for 1 hour, 
followed by stimulation with EGF. In comparison to the untreated cells, EGF-induced 
tyrosine phosphorylation of endogenous and exogenous Endofin in all Wortmannin-
treated cell lines was greatly diminished. Wortmannin has successfully inhibited the 
PI3K pathway as indicated by the loss of phosphorylated Akt (pS473) signal in 
Wortmannin-treated cells (Fig. 3.1.5A). Furthermore, as shown in Figure 3.1.5A, the 
phosphorylation of EGFR was not affected by the presence of Wortmannin, 
eliminating the possibility that Wortmannin treatment non-specifically interfered with 
EGFR activation. Taken together, the data implies that EGF-induced tyrosine 
phosphorylation of Endofin is dependent on PI3K activity.   
Since PI3K activity is required for tyrosine phosphorylation of Endofin, 
theoretically the FYVE domain that targets PI3P should be similarly required. To this 




bind PI3P, was first generated (Seet and Hong, 2001). Myc-tagged Endofin-WT and 
C753S mutant were then transfected into MCF10AT1K cells since they have good 
morphology for immunofluorescence (IF) studies. As in our previous report (Chen et 
al., 2007a), Endofin-WT largely co-localized in the perinuclear region in quiescent 
cells but radiated outwards with more punctate structures following stimulation with 
EGF (Fig. 3.1.5B). Co-localization of Endofin-WT with the early endosomal marker, 
EEA1, was also shown, indicating that these structures were endosomal in nature 
(Fig. 3.1.5C). In contrast, C753S mutant could neither localize properly as revealed 
by a homogenous distribution of Endofin throughout the non-stimulated or EGF-
stimulated MCF10AT1K cells, nor could it co-localize with EEA1 (Fig. 3.1.5B and 
C). Next, the C753S mutant or Endofin-WT, both myc-tagged, were co-transfected 
with EGFR into HEK293 cells (which have high transfection efficiency) and left 
untreated or stimulated with EGF. Endofin-WT and C753S mutant were then 
immunoprecipitated using anti-myc antibodies and probed for their tyrosine 
phosphorylation status. While Endofin-WT was tyrosine phosphorylated in EGF 
stimulated cells, no tyrosine phosphorylation of C753S mutant was observed (Fig. 
3.1.5D). Collectively, the data suggests that PI3K-mediated production of PI3P and 













Fig. 3.1.5A Endofin phosphorylation is dependent on PI3K activity 
A431, MCF10AT1K and HEK293 cells co-transfected with EGFR and myc-tagged 
Endofin-WT were serum-starved overnight, then either untreated or pretreated with 1 
μM of Wortmannin (W) for 1 h at 37°C before being left alone or stimulated with 50 
ng/mL of EGF for 2, 30 and 10 mins respectively. The cells were then harvested and 










Fig. 3.1.5B-C C753S Endofin mutant is unable to localize at the early endosomes 
(B) MCF10AT1K cells were transfected with either myc-tagged Endofin-WT or 
C753S mutant. After 48 h of protein expression and overnight serum starvation, the 
cells were stimulated with 50 ng/mL of EGF for the indicated time intervals. 
Immunofluorescence was then performed on these cells with anti-myc antibodies 
followed by secondary antibodies conjugated to AlexaFluor 488 (green). The nuclei 
were stained with DAPI (blue). Arrows indicate the punctate structures observed for 
wild-type Endofin. (C) Co-immunofluorescence was performed on C753S mutant-




















Fig. 3.1.5D Appropriate localization of Endofin is essential for its 
phosphorylation 
 
HEK293 cells were transfected with EGFR and myc-tagged Endofin-WT or C753S 
mutant, incubated at 37°C for 48 h to allow for protein expression and serum-starved 
overnight. The cells were then stimulated with EGF at 50 ng/mL for 2 mins, harvested 





















3.1.6 EGF-dependent co-localization of Endofin with EGFR requires a 
functional FYVE domain 
 
Although Endofin was found to co-localize with endocytosed EGF in A431 
cells, evidence for Endofin and EGFR existing together in the same compartment 
during EGFR trafficking has never been shown (Seet and Hong, 2001). Hence, the 
ability of Endofin to co-localize with endocytosed EGFR following EGF treatment 
was determined. To this end, co-IF studies of endogenous Endofin, EGFR, EEA1 and 
the lysosomal marker, CD63 were performed in MCF10AT1K cells over a time 
course. Figure 3.1.6A showed that at time zero, EGFR could be seen at the cell 
surface and within the cytoplasm while Endofin co-localized with EEA1 at the 
perinuclear region. No co-localization between EGFR and Endofin was detected at 
this point of time. After 10 minutes of EGF stimulation, prominent co-localization of 
Endofin with EGFR was observed in the cytoplasm spanning from the region 
proximal of the plasma membrane (but never at the plasma membrane) to the 
perinuclear area. At the same time, both EGFR and Endofin were detected to co-
localize with EEA1. This is consistent with the data in Figure 3.1.4A. However, it 
should be highlighted that co-localization was not always absolute and complete as 
some of the punctate structures were interspersed with green and red signals. This 
suggested the existence of a subset of EGFR and Endofin populations that did not co-
localize and that the EGFR/Endofin complex might be dynamically regulated. By 30 
minutes, most of the EGFR had co-localized with the lysosomal marker, CD63, 
indicating that the receptors were being targeted for degradation. On the other hand, 
little or no co-localization between Endofin and CD63 could be observed throughout 
the timecourse. Collectively, the results imply that EGFR and Endofin localize to the 




Since proper localization of Endofin is dependent on its FYVE domain, it is 
postulated that the FYVE domain maybe required for its co-localization with EGFR 
as well. To address this hypothesis, MCF10AT1K cells were co-transfected with 
EGFR and myc-tagged Endofin-WT or C753S mutant. Endofin-WT and C753S 
mutant transfected MCF10AT1K cells were either untreated or treated with EGF 
before co-IF of exogenous Endofin and EGFR was performed. Note that IF of 
Endofin-WT and mutant were achieved using anti-myc antibodies to detect only the 
exogenously expressed Endofin. EGFR was detected at the cell surface in non-
stimulated cells. Following EGF treatment, disappearance of EGFR from the cell 
surface (presumably due to endocytosis) was concomitant with its co-localization with 
Endofin-WT as indicated by the speckled yellow signals, which were a result of 
overlapping green and red fluorescent-labeled Endofin-WT and EGFR respectively, 
as they localize at the same location within the cells. In contrast, the distribution of 
the C753S mutant was diffuse and no co-localization with EGFR was observed (Fig 
3.1.6B). These data implies that a functional FYVE domain is necessary for Endofin 
















Fig. 3.1.6A EGFR and Endofin co-localize at EEA1-positive endosomes  
 
MCF10AT1K cells were serum-starved and stimulated with 50 ng/mL of EGF for the 
indicated timepoints. The cells were then fixed and stained with anti-EGFR, Endofin, 


























Fig. 3.1.6B Co-localization of Endofin with EGFR requires its FYVE domain  
 
MCF10AT1K cells were co-transfected with EGFR and either myc-tagged Endofin-
WT or C753S mutant, serum-starved overnight and stimulated with 50 ng/mL of EGF 
for 10 mins. The cells were fixed and stained with anti-EGFR (red) and anti-myc 


















3.2       Determination of Endofin tyrosine phosphorylation site and function  
 Phosphorylation is one of the most common post-translational protein 
modifications in mammalian cells. Serine, threonine and tyrosine are the amino acids 
that are phosphorylated in mammalian cells. It was shown that serine, threonine and 
tyrosine phosphorylation occurs with relative abundances of 86.4%, 11.8% and 1.8% 
respectively (Olsen et al., 2006). Although tyrosine phosphorylation is the minority, it 
has a profound impact on a protein’s biological activity. It regulates many important 
aspects of a protein function including protein activities, protein-protein interactions 
and subcellular localization (Cohen, 2000). Growth factor receptors are a major group 
of proteins whose activities are tightly controlled by tyrosine phosphorylation 
(Dengjel et al., 2009). Since Endofin is identified as a tyrosine phosphorylation target 
of EGF signaling, it evidently suggests that a particular function of Endofin is 
regulated by tyrosine phosphorylation.  
 
3.2.1    Tyrosine 515 is a major phosphorylation site of Endofin   
 
To facilitate the study on the role of tyrosine phosphorylation of Endofin, an 
attempt was made to identify the tyrosine phosphorylation sites on Endofin. Potential 
sites were first predicted using the PhosphoMotif Finder algorithm from the Human 
Protein Reference Database (http://www.hprd.org). A total of 41 sites were predicted 
where 5 (Y28, Y515, Y998, Y1201, Y1381) sites corresponded to the EGFR kinase 
motif, a short amino acid sequence that is recognized by EGFR kinase for 
phosphorylation. These sites were thus selected for further investigation since Endofin 
is a phosphorylation target of EGF signaling. In addition, Tyrosine 221 was included 
for verification as it was previously reported to be phosphorylated in pervanadate-












Table 3.2.1 Predicted tyrosine phosphorylation sites on Endofin  
Tyrosine phosphorylation sites on Endofin were predicted with a program from the 












Endofin Y Æ F mutants based on the predicted sites were generated. Myc-tagged 
Endofin-WT and mutants were then co-transfected with EGFR into HEK293 cells. 
Cells were untreated or stimulated with EGF and the tyrosine phosphorylation levels 
of immunoprecipitated Endofin-WT and mutants were determined by immunoblotting 
with PY20H. From a total of 4 independent experiments, there was no significant 
change in the phosphorylation status of all but one mutant, Y515F, whose 
phosphorylation dropped by 72% (p-value = 0.015 based on the non-parametric Mann 
Whitney U test), in comparison to Endofin-WT (Fig. 3.2.1A and B). As the 
phosphorylation of Y515F was not completely abolished, it implied that the Tyrosine 
515 (Y515) is a major phosphorylation site but it is not the only site on Endofin. In 
order to validate if the residual phosphorylation of Y515F mutant was contributed by 
the other predicted sites with minor phosphorylation changes, a double Endofin 
mutant, consisting of mutations at Y28 and Y221, was generated and had its 
phosphorylation level assessed. Y515F and C753S were added into the experiment to 
act as control and for comparison purposes. Overall, there was no reduction of the 
phosphorylation level of the double mutant, Y28/221F, as compared to the Endofin-
WT (Fig. 3.2.1C). Hence, this verifies that Tyrosine 28 and 221 are not 
phosphorylation sites on Endofin as mutations at both sites did not produce any 
changes in Endofin phosphorylation level.   
Next, to further confirm the above results, an in vitro kinase assay was 
performed to determine if Y515 phosphorylation could be recapitulated in vitro using 
purified EGFR kinase. HEK293 cells were first transfected with myc-tagged Endofin-
WT and various mutants. After 48 hours of protein expression and overnight serum-
starvation to express minimally phosphorylated Endofin substrate, myc-tagged 




and subjected to the in vitro kinase assay. Consistent with Figure 3.2.1A, very low 
phosphorylation signal of Y515F was obtained compared to Endofin-WT (Fig. 
3.2.1D). On the other hand, neither the single Y28F nor the double Y28/221F Endofin 
mutant displayed any decrease in their phosphorylation level. C753S mutant was 
included in the in vitro kinase assay to determine whether it remains as a substrate of 
EGFR. As seen in Figure 3.2.1D, C753S mutant could be tyrosine phosphorylated in 
vitro. This suggests that the inability of C753S mutant to be tyrosine phosphorylated 
in vivo (as seen Fig. 3.1.5D) was not due to structural artifact arising from the 
mutation but from the disruption of Endofin’s proper localization. Given that Endofin 
can be phosphorylated by the active EGFR kinase in the in vitro kinase assay, the 
results imply that Endofin is a direct substrate of EGFR, although the participation of 
an intermediary kinase cannot be ruled out. Taken together, the data supports the 


























Fig. 3.2.1A-B Y515 of Endofin is a major phosphorylation site for EGFR  
 
(A) HEK293 cells were transfected with EGFR and myc-tagged Endofin-WT or 
mutants, incubated at 37°C for 48 h to allow for protein expression and serum-starved 
overnight. The cells were then stimulated with EGF for 2 mins, harvested and the 
lysates used for immunoprecipitation and immunoblotting with various antibodies. 
(B) Mean relative phosphorylation levels of Endofin wild-type (n=4) and Y515F 














Fig. 3.2.1C-D Endofin is a direct substrate of EGFR 
(C) HEK293 cells were transfected with EGFR and myc-tagged Endofin-WT or 
mutants, incubated at 37°C for 48 h to allow for protein expression and serum-starved 
overnight. The cells were then stimulated with EGF for 2 mins, harvested and the 
lysates used for immunoprecipitation and immunoblotting with various antibodies. 
(D) HEK293 cells were transfected with myc-tagged Endofin-WT and various 
mutants and serum-starved overnight after 48 h of protein expression. Transfected 
cells were harvested and Endofin-WT as well as various mutants were 
immunoprecipitated out with anti-myc antibodies. Immunoprecipitated Endofin-WT 
and mutants were then subjected to phosphorylation by active EGFR kinase in the in 
vitro kinase assay. The eluted proteins were then resolved by gel electrophoresis and 






3.2.2 Phosphorylation at Y515 does not affect the localization of Endofin and 
its co-localization with EGFR 
 
After determining Y515 as a major Endofin phosphorylation site, the 
possibility of Y515 phosphorylation regulating Endofin’s localization was 
subsequently investigated. To do this, MCF10AT1K cells were first co-transfected 
with myc-tagged Endofin-WT or Y515F mutant and then stimulated with EGF for the 
indicated timepoints. Localization of myc-tagged Endofin-WT and mutant was then 
examined using anti-myc antibodies to detect the exogenous Endofin proteins. The 
results showed that EGF-induced localizations of Endofin-WT and Y515F mutant 
were similar (Fig. 3.2.2A). Beside this, the Y515F mutant was able to co-localize with 
EEA1 in a similar manner as the Endofin-WT, indicating that phosphorylation does 
not affect Endofin’s localization to the endosomes (Fig. 3.2.2B). 
 In addition to endosomal localization, Endofin was also shown to co-localize 
with endocytosed EGF in the endosomes (Seet and Hong, 2001). Hence, the effect of 
Y515 phosphorylation on EGF-induced co-localization of Endofin with EGFR was 
examined as well. MCF10AT1K cells were co-transfected with EGFR and either 
Endofin-WT or Y515F mutant and stimulated with EGF. Co-IF was then performed 
to assay for co-localization of EGFR and Endofin, which was probed with anti-myc 
antibodies to detect only the exogenous proteins. No co-localization of Endofin-WT 
or Y515F mutant with EGFR was observed in unstimulated cells (Fig. 3.2.2C). 
Yellow signals arising from the co-localization of green fluorescent-labeled Endofin 
and red fluorescent-labeled EGFR could be observed in both Endofin-WT and Y515F 
mutant expressing cells upon EGF stimulation, indicating that tyrosine 
phosphorylation at Y515 has no effect on Endofin’s co-localization with EGFR (Fig. 
3.2.2C). Taken together with the data presented in Section 3.1.5, it implies that proper 








Fig. 3.2.2A-B  Endosomal localization of Endofin is not dependent on its Y515      
phosphorylation  
 
(A) MCF10AT1K cells were transfected with myc-tagged Endofin-WT and Y515F 
mutant, serum-starved and stimulated with 50 ng/mL of EGF over a time course. IF 
was then performed on these cells with anti-myc (green) antibody. (B) Co-IF was 
performed on MCF10AT1K cells transfected with Endofin-WT and Y515F mutant 























Fig. 3.2.2C Co-localization of Endofin with EGFR does not require Y515 
phosphorylation  
 
MCF10AT1K cells were co-transfected with EGFR and myc-tagged Endofin-WT or 
Y515F mutant. After 48 h of protein expression and overnight serum starvation, the 
cells were stimulated with 50 ng/mL of EGF for 10 mins and co-IF performed on 
these cells with anti-myc (green) and anti-EGFR (red) antibodies followed by 

















3.2.3  Endofin’s localization and phosphorylation increased the amplitude of 
EGF-induced MAPK pathway 
 
The reported delay in EGFR trafficking to lysosomes detected in Endofin 
overexpressing A431 cells offered the possibility that Endofin may be involved in the 
modulation of EGFR signaling (Seet and Hong, 2001). To begin with, the effect of 
Endofin overexpression on EGFR signaling was first assessed. A few cell lines 
including HEK293, MCF10AT1K and Hela cells were screened to identify a cell line 
that has high transfection efficiency and at the same time expresses the lowest level of 
endogenous Endofin for transfection studies. This is to select an appropriate cell line 
in which any potential interference by endogenous protein on the transfected proteins 
is minimized. The Hela cell line was found to express the least endogenous Endofin 
(Fig.3.2.3A). Hence, myc-tagged Endofin-WT was transfected into Hela cells which 
were stimulated with EGF and harvested. The lysates were then analyzed with 
antibodies specific to various signaling proteins found within EGFR signaling 
pathways. Based on Figure 3.2.3B, overexpression of Endofin did not result in any 
significant changes in Akt or MAPK activities. On top of this, there was no visible 
difference in EGFR modulation of Endofin overexpressing cells in comparison to the 
control cells. This result differs from the reported observation of Endofin 
overexpression in A431 (Seet and Hong, 2001). The discrepancy in results may be 
due to the different cell lines used. As mentioned in the earlier section, A431 exhibits 
insignificant EGFR downregulation and a high recycling rate; Hela cells, on the hand, 
show typical EGFR modulation (as shown in Fig. 3.2.3B). Hence, it is not unexpected 








Fig. 3.2.3A Endofin expression and transfection efficiency in various cell lines 
 
HEK293, MCF10AT1K and Hela cells were transfected with Endofin-WT and the 
lysates were probed with anti-Endofin antibodies to determine the endogenous 
Endofin expression level as well as the transfection efficiencies of the cells. UT = 





Fig. 3.2.3B Endofin overexpression has no effect on EGFR modulation or 
signaling 
 
Hela cells are transfected with either an empty vector as control or myc-tagged 
Endofin-WT, serum-starved and stimulated with 50 ng/mL of EGF for the indicated 




With accumulating evidence showing the importance of FYVE domain in 
mediating co-localization and Y515 as a site of phosphorylation by EGFR, the role of 
the FYVE domain and Y515 phosphorylation of Endofin in the modulation of EGFR 
signaling was next elucidated. To investigate the role of Y515 phosphorylation and 
localization of Endofin on EGFR signaling, myc-tagged Endofin-WT, Y515F and 
C753S mutants were transfected into Hela cells, which were then starved overnight 
before stimulation with EGF over a time course. The activation status of EGFR, Akt 
and MAPK were interrogated via a combination of immunoprecipitation and/or 
immunoblotting. Three independent experiments were conducted and one 
representative set of data is shown in Figure 3.2.3C. Similar to Endofin-WT, no 
apparent effect of Endofin Y515 phosphorylation on the kinetics of EGFR auto-
phosphorylation, the Ras/MAPK and the PI3K/Akt signaling pathways downstream of 
EGFR was observed. In contrast, while phosphorylation of ERK1 and ERK2 rapidly 
peaked and fell at 2 minutes and 30 minutes following EGF stimulation of Endofin-
WT expressing cells, mis-localization of Endofin (C753S mutant) significantly 
enhanced ERK1 and ERK2 activation by 4 and 2 folds at 2 minutes, respectively (Fig. 
3.2.3D). At the same time, C753S mutant prolonged the activated ERK cascade as 
reflected by the more intense pERK1/2 signal at 30 minutes compared to cells 
transfected with Endofin-WT.  
It is possible that the failure to detect any effect of Y515F mutant on EGFR 
signaling was caused by interference from endogenous Endofin. Hence the 
experiment was repeated by first reducing the endogenous level of Endofin using 
Endofin-specific siRNA. To do this, siRNA that targets the 3’ untranslated region 
(3’UTR) of Endofin mRNA was used so as to achieve reduction of endogenous 







Fig. 3.2.3C-D Mislocalization of Endofin amplified EGF-induced MAPK 
signaling  
 
(C) Hela cells were transfected with myc-tagged Endofin-WT, Y515F or C753S 
mutant, serum-starved and stimulated with 50 ng/mL of EGF for the indicated time 
intervals. The cells were then harvested and lysates used for analysis with the various 
antibodies. (D) Mean relative Erk1/2 activity in cells expressing Endofin wild-type 
(n=3, grey) and C753S mutant (n=3, white) were shown.  




tagged Endofin were transfected either alone or together into Hela cells and their 
Endofin level was examined. Endofin level in cells transfected with the 3’UTR 
siRNA alone was greatly reduced in comparison to the un-transfected (UT) control, 
while the siRNA showed  no effect on the expression of myc-tagged Endofin as seen 
in cells co-transfected with 3’UTR siRNA and myc-tagged Endofin (Fig. 3.2.3E). 
Next, 3’UTR siRNA was co-transfected together with myc-tagged Endofin-WT or 
Y515F mutant into Hela cells and the activation status of EGFR, Akt and MAPK was 
examined. As before, no change in PI3K/Akt signaling pathway in cells expressing 
Y515F was observed (Fig. 3.2.3F). However, Y515F mutant could now be observed 
to enhance the activation of ERK2 by 82% (Fig. 3.2.3G). From a total of 3 
independent experiments, this effect was determined to be statistically significant (p-
value of 0.05 based on the non-parametric Mann Whitney U test). Although ERK1 
activity was also slightly elevated in Y515F expressing cells, the effect was not 
statistically significant. Evidently, the effect of C753S mutant on MAPK pathway was 
greater than that of the Y515F mutant. This was not surprising as mutation at C753 
caused a complete disruption of Endofin’s localization and cellular 
compartmentalization within the cell has been shown to play a significant role in a 
protein’s functions (Henis et al., 2009). As for the subtle effect produced by the 
Y515F mutant, it may be attributed to the low resolution at which MAPK signaling 
was determined. MAPK signaling has been observed to occur at several locations 
within the cell, such as the plasma membrane, Golgi apparatus, early and late 
endosomes (Omerovic and Prior, 2009) and these MAPK signals can mask off the 
effects of Y515F mutant. Hence it may be necessary to focus on the particular 
compartment that Endofin resides and function at in order to achieve a better 




Nonetheless, based on these data, the localization and less prominently, Y515 








Fig. 3.2.3E-G Y515F mutant increased MAPK2 activity in Endofin knockdown 
cells   
(E) Hela cells were transfected with either 3’UTR siRNA and myc-tagged Endofin 
alone or together and their Endofin level detected with Endofin antibody. (F) Hela 
cells were co-transfected with 3’UTR siRNA and either myc-tagged Endofin-WT or 
Y515F mutant, serum-starved and stimulated with 50 ng/mL of EGF for the indicated 
time intervals. The cells were then harvested and lysates used for analysis with the 
various antibodies. (G) Mean relative Erk1/2 activity in cells expressing Endofin-WT 






3.2.4 Proliferation rates of Y515F and C753S expressing cells were elevated  
Growth stimulatory effects of EGFR signaling are mediated through its 
various downstream signaling pathways. As MAPK signaling was amplified in 
Y515F and C753S expressing cells, these signals may be translated to increased 
proliferation rates. Hence, the proliferation rates of Y515F and C753S expressing 
cells were determined. Myc-tagged Endofin-WT, Y515F and C753S were expressed 
in endogenous Endofin knockdown Hela cells, stimulated with EGF and their 
proliferation rates determined with MTS assay for four consecutive days. Due to the 
toxicity caused by 3’ UTR siRNA transfection, the transfected Hela cells were unable 
to survive under complete serum-starvation condition. Hence instead of completely 
depriving the cells of serum, the cells were incubated with 1% of serum before 
stimulation with EGF in order to sustain cell growth. Indeed, Y515F and C753S 
expressing cells proliferated faster than Endofin-WT expressing cells (Fig. 3.2.4). By 
the third day of the experiment, the number of viable Y515F and C753S expressing 
cells were 1.8-fold and 2.3-fold higher than Endofin-WT expressing cells 
respectively. This implies that localization and phosphorylation of Endofin may 









































Fig. 3.2.4 Y515F and C753S expressing cells have increased proliferation rates  
Hela cells were co-transfected with Endofin 3’ UTR siRNA and myc-tagged Endofin-
WT, Y515F or C753S. 1000 transfected cells were then seeded into each well of a 96-
well plate. The cells were stimulated with 50 ng/mL of EGF for 3 days whereby the 
number of viable cells was determined each day with MTS assay. The average of 



















Chapter 4  
Discussion 
4.1       Endofin’s regulatory actions on EGFR signaling   
Endofin was first implicated in EGF signaling when its overexpression 
resulted in endosomal aggregates formation that accumulated endocytosed EGF (Seet 
and Hong, 2001). However, its role in EGF signaling has never been characterized 
further until it was reported in a study that EGFR activity was required for tyrosine 
phosphorylation and the translocation of Endofin to the early endosomes (Chen et al., 
2007a). This study further contributed to the understanding of Endofin in EGF 
signaling. Based on the data presented, a model shown in Figure 4.1 was proposed. 
Binding of EGF to EGFR induces the internalization of EGF/EGFR complex, leading 
to the formation of activated EGFR-containing endosomes with the receptor’s 
carboxyl-terminal tail exposed in the cytosol of the cell. This process is essential as 
endocytosis brings EGFR from the plasma membrane into the cytosol, a location 
where Endofin can be found as well. At the same time, EGFR activates PI3K which in 
turn produces PI3P on the endosomal membrane. Endofin then translocates to the 
endosomes by binding to the PI3Ps via their FYVE domain. This facilitates tyrosine 
phosphorylation of Endofin at Y515, possibly by EGFR. The proper localization of 
Endofin that precedes its phosphorylation is consistent with the observation that 
proper localization of Endofin at endosomes is required for Endofin phosphorylation 
but not vice versa. The necessity of clathrin-dependent endocytosis of EGFR for 
Endofin phosphorylation also supports this view because endocytosis leads to the 
formation of EGFR/PI3P-containing endosomes whereby Endofin can localize to and 
without which Endofin phosphorylation is severely compromised. At the endosomes, 




be elucidated. No effect of Endofin’s phosphorylation and localization was observed 
on the Akt pathway suggesting that the PI3K/Akt pathway is probably de-coupled 
from the endosomal EGFR/Endofin complex following Endofin’s translocation and 
phosphorylation.  
As with most models, Figure 4.1 raises more questions than answers. What is 
the kinase responsible for Endofin tyrosine phosphorylation? Based on the results, 
EGFR was the prime suspect. Circumstantial evidence that point to EGFR include i) 
the sequence flanking Y515 fits the consensus motif for EGFR substrates; ii) co-
localization of Endofin and EGFR at the endosomes was observed and iii) in vitro 
kinase assay showed that Y515 of Endofin-WT can be phosphorylated by EGFR but 
not Y515F mutant (Fig. 3.2.1D). However, the in vitro kinase assay data is prone to 
over-interpretation since most kinases are rather promiscuous in vitro. Although iv) 
Iressa treatment abrogated EGFR-mediated tyrosine phosphorylation of Endofin 
suggests EGFR as the kinase for Y515 in Endofin, it is not a direct evidence as 
inhibition of EGFR with Iressa can result in the inactivation of kinases downstream of 
the receptor as well (Chen et al., 2007a).  
Despite all these evidence supportive of EGFR as Endofin’s kinase, there still 
exists the possibility of Endofin being phosphorylated by an intermediary kinase. Src 
is a non-receptor tyrosine kinase acting downstream of EGFR. Upon the activation by 
EGFR, Src is able to participate in a number of receptor-mediated cellular processes 
such as cytoskeleton reorganization, cell motility and survival (Bromann et al., 2004). 
Recently, EGFR and Src were demonstrated to traffick together in endosomal 
compartments during EGF stimulation (Donepudi and Resh, 2008). This thereby 
places Src at the same location where Endofin phosphorylation occurs. Hence there is 




sequence flanking Y515 matches to the Src family kinase substrate motif, thus 
providing further evidence that Endofin can be a phosphorylation target of Src kinase. 
In view of all these circumstantial evidence, further experiments are necessary to 





Fig. 4.1 Schematic diagram of Endofin’s role in EGFR signaling 
EGF binds to EGFR, activates EGFR and induces its internalization. PI3K is then 
recruited and activated by EGFR, leading to the production of PI3P. Endofin localizes 
to the endosome via its binding with PI3P on the endosomal membrane and FYVE 
domain. This results in the phosphorylation of Endofin at Y515 that may be mediated 
by EGFR. Through an unknown mechanism, localization and phosphorylation of 











4.2       Possible mechanisms utilized by Endofin in regulation of MAPK signaling   
In this study, a putative role for Endofin in the regulation of MAPK pathway 
was revealed. Disruption of proper localization to the endosomes and less 
pronouncedly the Y515 phosphorylation of Endofin enhanced MAPK activation. This 
suggests that Endofin negatively modulates EGFR signaling following receptor 
endocytosis. This data also adds onto the accumulating evidence of continuous 
receptor signaling from the endosomes. It is not entirely clear how Endofin turned off 
MAPK. However, in a prediction of functional sites in Endofin through the usage of 
ELM (Eukaryotic Linear Motif) resource database, 2 sites on Endofin were identified 
as MAPK docking motifs, thereby suggesting that Endofin may be able to interact 
with MAPK. With this prediction, it is possible that Endofin acts as a scaffold protein 
that helps to regulate trafficking of signaling receptors or localize signaling 
complexes to specific endocytic compartments.  
Scaffold proteins are multidomain proteins involved in the regulation of 
MAPK signaling. They provide platforms whereby various components of the MAPK 
cascade can bind to, thus forming signaling complexes at specific locations within the 
cell and facilitate efficient propagation of the signal (Pawson and Scott, 1997). In this 
manner, they not only control the kinetics, amplitude and localization of MAPK 
signaling but confer specificity to the signal as well (Chang and Karin, 2001). A 
number of scaffold proteins that possess regulatory roles in MAPK signaling have 
been identified and these include KSR (Kinase suppressor of Ras), IQGAP1, β-
arrestins, MP1 and Sef. MP1 (MEK1 partner 1) forms a MAPK scaffold complex at 
the late endosomes, consisting of p18, p14, MEK1, ERK1 and ERK2, and is 
responsible for full ERK1/2 activation in the later phase of signaling (Nada et al., 




the phosphorylation of ERK1/2 by MEK1 by bringing them together at a specific 
location as the lack of either p14 or p18 leads to the reduction of ERK1/2 and 
MEK1/2 activity (Teis et al., 2006). Mis-localization of the MP1/p14 complex to the 
plasma membrane led to the reduction of ERK activity, indicating that localization of 
the scaffold at the specific location is essential for MP1 scaffold function. This is 
similar to the observations that were made on Endofin, whereby the mislocalized 
C753S Endofin mutant caused an enhancement of ERK1/2 activity, hence suggesting 
the spatial regulatory scaffold function that Endofin may possess. Sef (Similar 
expression to FGF) is a MEK/ERK scaffold protein that resides at the Golgi 
apparatus. It acts as a negative spatial regulator of FGF (fibroblast growth factor)-
induced MAPK signaling, whereby it sequesters active MEK/ERK complexes at the 
Golgi, therefore preventing the nuclear translocation of ERK and its interaction with 
its nuclear effectors (Torii et al., 2004). In EGF signaling, Sef is shown to co-localize 
with EGFR at the early endosomes and enhances EGF-induced MAPK signaling by 
delaying EGFR degradation (Ren et al., 2008). A hypothesis on how Endofin may 
regulate MAPK signaling with a similar sequestration mechanism can be drawn based 
on the Sef mechanism. This is because the loss of proper localization of Endofin not 
only increases ERK activity but its proliferation rate as well. This suggests an increase 
in ERK translocation into the nucleus and activation of target genes expression. 
Therefore it is possible that Endofin functions by capturing inactive MEK/ERK and 
preventing excessive MAPK signaling at the early endosomes. Alternatively, it may 
recruit a phosphatase to the activated MEK/ERK that it is associated with to 
deactivate the kinases as a way of controlling the signaling.   
Another possible mechanism that may be utilized by Endofin to regulate 




Y515 complies with the pYXNX motif that binds preferentially to the SH2 domain of 
GRB2 (Pawson, 1995; Pawson et al., 2001). It is thus conceivable that the 
phosphorylated Y515 on Endofin binds to SH2 domain of Grb2 and competes off 
GRB2/SOS from EGFR. This in turn disrupts the close proximity of GRB2/SOS 
complex with Ras thereby terminating the activation of Ras/Raf/MEK/ERK pathway. 
On the other hand, Grb2’s involvement in EGFR trafficking may provide another way 
for Endofin to regulate MAPK signaling. Endofin’s association with Grb2 will also 
lead to the sequestration of Grb2-binding proteins involved in EGFR trafficking. This 
in turn may affect trafficking or sorting of the receptors and indirectly regulates 
EGFR signaling at the endosomes.   
 
4.2       Future areas of research  
The proposed hypotheses of mechanisms that may be utilized by Endofin in 
the regulation of MAPK signaling warrant further validation. Interaction between 
Grb2 and sequestration of MEK/MAPK by Endofin has to be determined in order to 
verify the hypotheses. Large scale protein interaction studies to identify interacting 
partners of Endofin involving in MAPK signaling are currently being carried out. This 
should help to provide more clues and aid in the understanding of the mechanism 
through which Endofin modulates MAPK pathway.  
 In EGFR trafficking, EGFR can either be degraded or recycled back to the 
plasma membrane. The fate of EGFR is highly dependent on the sorting process that 
occurs at the early endosomes. Given that Endofin is detected at the early endosomes 
and overexpression of Endofin caused accumulation of endocytosed EGF in 
endosomal aggregates, these results implicate Endofin in EGFR sorting process. Hrs, 




sorting and signaling. Interestingly, Endofin and Hrs share several similarities. Firstly, 
both proteins bind to PI3P in the early endosomal membrane via their FYVE domains. 
Secondly, inhibition of endocytosis by dominant-negative dynamin reduces EGF-
induced phosphorylation of Endofin and Hrs. Thirdly, like Endofin, proper EGF-
induced localization of Hrs at the early endosomes is required for its tyrosine 
phosphorylation (Bache et al., 2002; Stern et al., 2007; Urbe et al., 2000). Fourthly, 
both proteins are associated with EGFR. Although Endofin has been shown to be a 
direct phosphorylation target of EGFR in the in vitro kinase experiment, direct 
interaction between the two proteins has never been proven. Hrs, on the other hand, is 
shown to interact with EGFR through STAM proteins (Morino et al., 2004). Fifthly, 
both proteins are able to recruit clathrin to the early endosomes, whereby Hrs binds to 
clathrin via its clathrin box motif and Endofin via TOM1 (Raiborg et al., 2001a; Seet 
and Hong, 2005). This close resemblance between Endofin and Hrs, in terms of its 
tyrosine phosphorylation properties and interacting partners, suggests that the two 
proteins may share a common pathway within the trafficking process or may even 
have potential cooperative/antagonistic roles in EGFR sorting/trafficking. TOM1 is 
another interacting protein of Endofin that is identified to recruit clathrin to the early 
endosomes. Investigating on the relationship of Endofin with TOM1 and Hrs with 
regards to EGFR trafficking may provide interesting information on Endofin’s role in 
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